
(
  (S
    (NP
      (NP
        (NP (NN Resistance))
        (PP (TO to)
          (NP
            (NP
              (NP (NN IL-10))
              (NN inhibition))
            (PP (IN of)
              (NP
                (NP (NN interferon) (NN gamma))
                (NN production))))))
      (CC and)
      (NP
        (NP (NN expression))
        (PP (IN of)
          (NP
            (NP (NN suppressor))
            (PP (IN of)
              (NP (NN cytokine) (NN signaling) (CD 1)))))
        (PP (IN in)
          (NP
            (NP (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP
                (NP (NNS patients))
                (PP (IN with)
                  (NP (JJ rheumatoid) (NN arthritis)))))))))))

(
  (S
    (NP (NN Abstract))))

(
  (S
    (S
      (NP (NN IL-10))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN shown)
            (S
              (VP (TO to)
                (VP (VB block)
                  (NP (DT the) (JJ antigen-specific) (NN T-cell) (NN cytokine) (NN response))
                  (PP (IN by)
                    (S
                      (VP (VBG inhibiting)
                        (NP (DT the) (NN CD28) (NN signaling) (NN pathway))))))))))))
    (. .)))

(
  (S
    (NP (PRP We))
    (VP (VBD found)
      (SBAR (IN that)
        (S
          (NP
            (NP (JJ peripheral) (NN blood) (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP
                (NP (NNS patients))
                (PP (IN with)
                  (NP
                    (NP (JJ active) (JJ rheumatoid) (NN arthritis))
                    (PRN (-LRB- -LRB-)
                      (NP (NN RA))
                      (-RRB- -RRB-)))))))
          (VP (VBD were)
            (ADJP (JJ able)
              (S
                (VP (TO to)
                  (VP (VB produce)
                    (NP
                      (NP (JJR greater) (NNS amounts))
                      (PP (IN of)
                        (NP (NN interferon) (NN gamma))))
                    (PP (IN after)
                      (NP
                        (NP (NN CD3))
                        (CC and)
                        (NP (NN CD28))
                        (NP (NN costimulation))))
                    (PP (IN in)
                      (NP
                        (NP (DT the) (NN presence))
                        (PP (IN of)
                          (NP
                            (ADJP (CD 1) (NN ng/ml))
                            (NN IL-10)
                            (SBAR (IN than)
                              (SINV (VBD were)
                                (NP (JJ normal) (NN control) (JJ CD4+) (NN T) (NNS cells))))))))))))
            (, ,)
            (SBAR (IN although)
              (S
                (NP
                  (NP (PRP$ their) (NN surface) (NN expression))
                  (PP (IN of)
                    (NP (DT the) (NN type) (CD 1) (NN IL-10) (NN receptor))))
                (VP (VBD was)
                  (VP (VBN increased)))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (DT The) (NN phosphorylation))
          (PP (IN of)
            (NP
              (NP
                (NP (NN signal) (NN transducer))
                (CC and)
                (NP (NN activator)))
              (PP (IN of)
                (NP (NN transcription) (CD 3))))))
        (VP (VBD was)
          (VP (VBN sustained)
            (PP (IN in)
              (NP
                (NP
                  (NP (CC both)
                    (NP (NN blood))
                    (CC and)
                    (NP (JJ synovial) (NN tissue)))
                  (JJ CD4+) (NN T) (NNS cells))
                (PP (IN of)
                  (NP (NN RA))))))))
      (, ,)
      (CC but)
      (S
        (NP (PRP it))
        (VP (VBD was) (RB not)
          (VP (VBN augmented)
            (PP (IN by)
              (NP
                (NP (DT the) (NN presence))
                (PP (IN of)
                  (NP
                    (ADJP (CD 1) (NN ng/ml))
                    (NN IL-10)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Sera))
        (PP (IN from)
          (NP (NN RA) (NNS patients))))
      (VP (VBD induced)
        (NP
          (NP
            (NP
              (NP (NN signal) (NN transducer))
              (CC and)
              (NP (NN activator)))
            (PP (IN of)
              (NP (NN transcription) (CD 3))))
          (NN phosphorylation))
        (PP (IN in)
          (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells)))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (VP (VBD was)
              (ADVP (RB mostly))
              (VP (VBN abolished)
                (PP (IN by)
                  (S
                    (VP (VBG neutralizing)
                      (NP (JJ anti-IL-6) (NN antibody)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Preincubation))
        (PP (IN of)
          (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells)))
        (PP (IN with)
          (NP (NN IL-6))))
      (VP (VBD reduced)
        (NP
          (NP (JJ IL-10-mediated) (NN inhibition))
          (PP (IN of)
            (NP (NN interferon) (NN gamma) (NN production))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Blood) (JJ CD4+) (NN T) (NNS cells))
        (PP (IN from)
          (NP (NN RA) (NNS patients))))
      (VP (VBD contained)
        (NP
          (NP
            (NP (JJR higher) (NNS levels))
            (PP (IN of)
              (NP
                (NP (NN suppressor))
                (PP (IN of)
                  (NP (NN cytokine) (NN signaling) (CD 1))))))
          (CC but)
          (NP
            (NP (JJR lower) (NNS levels))
            (PP (IN of)
              (NP
                (NP (NN suppressor))
                (PP (IN of)
                  (NP (NN cytokine) (NN signaling) (CD 3) (NN mRNA)))))))
        (PP (VBN compared)
          (PP (IN with)
            (NP (NN control) (JJ CD4+) (NN T) (NNS cells))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN determined)
              (PP (IN by)
                (NP (JJ real-time) (NN PCR))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBP indicate)
        (SBAR (IN that)
          (S
            (S
              (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))
              (VP (VBP become)
                (ADJP (JJ resistant)
                  (PP (TO to)
                    (NP
                      (NP (DT the) (JJ immunosuppressive) (NN effect))
                      (PP (IN of)
                        (NP (NN IL-10))))))
                (PP (IN before)
                  (NP
                    (NP (NN migration))
                    (PP (IN into)
                      (NP (JJ synovial) (NN tissue)))))))
            (, ,)
            (CC and)
            (S
              (NP (DT this) (JJ impaired) (NN IL-10) (NN signaling))
              (VP (MD may)
                (VP (VB be)
                  (VP (VBN associated)
                    (PP (IN with)
                      (NP
                        (NP
                          (NP
                            (NP
                              (NP (JJ sustained) (NN signal) (NN transducer))
                              (CC and)
                              (NP (NN activator)))
                            (PP (IN of)
                              (NP (NN transcription) (CD 3))))
                          (NN activation))
                        (CC and)
                        (NP
                          (NP (NN suppressor))
                          (PP (IN of)
                            (NP (NN cytokine) (NN signaling) (CD 1))))
                        (NP (NN induction))))))))))))
    (. .)))

(
  (S
    (NP (NN Introduction))))

(
  (S
    (S
      (NP (NN IL-10))
      (VP (VBZ is)
        (NP (DT a) (JJ key) (NN cytokine))
        (PP (IN in)
          (S
            (VP (VBG regulating)
              (NP (JJ inflammatory) (NNS responses)))))
        (, ,)
        (PP
          (ADVP (RB mainly))
          (IN by)
          (S
            (VP (VBG inhibiting)
              (NP
                (NP (DT the)
                  (NP (NN production))
                  (CC and)
                  (NP (NN function)))
                (PP (IN of)
                  (NP (JJ proinflammatory) (NNS cytokines)))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-10))
      (VP (VBZ binds)
        (PP (TO to)
          (NP
            (NP (DT the)
              (NP
                (NP (NN IL-10) (NN receptor))
                (PRN (-LRB- -LRB-)
                  (NP (NN IL-10R))
                  (-RRB- -RRB-)))
              (NN complex))
            (SBAR
              (WHNP (WDT that))
              (S
                (VP (VBZ is)
                  (VP (VBN composed)
                    (PP (IN of)
                      (NP
                        (NP (CD two) (NNS subunits))
                        (, ,)
                        (NP
                          (NP
                            (NP (DT the) (JJ primary) (JJ ligand-binding) (NN component) (NN type) (CD 1) (NN IL-10R))
                            (PRN (-LRB- -LRB-)
                              (NP (NN IL-10R1))
                              (-RRB- -RRB-)))
                          (CC and)
                          (NP (DT the) (NN accessory) (NN component) (NN type) (CD 2) (NN IL-10R) (CD -LSB-1) (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (NN interaction))
      (PP (IN of)
        (NP
          (NP (NN IL-10))
          (CC and)
          (NP (NN IL-10R)))))
    (VP (VBZ engages)
      (NP
        (NP
          (NP (DT the) (NN Janus) (NN kinase) (-LRB- -LRB-) (NN JAK) (-RRB- -RRB-) (NN family) (NN tyrosine) (NNS kinases))
          (NP
            (NP (NN Jak1))
            (CC and)
            (NP (NN Tyk2))))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (VP (VBP are)
              (ADVP (RB constitutively))
              (VP (VBN associated)
                (PP (IN with)
                  (NP
                    (NP (NN IL-10R1))
                    (CC and)
                    (NP (NN type) (CD 2) (NN IL-10R))
                    (, ,)
                    (ADVP (RB respectively))
                    (NP (NN -LSB-2))))))))))
    (-RRB- -RSB-) (. .)))

(
  (S
    (S
      (NP (NN IL-10))
      (VP (VBZ induces)
        (NP
          (NP (NN tyrosine) (NN phosphorylation))
          (CC and)
          (NP
            (NP (NN activation))
            (PP (IN of)
              (NP (DT the) (JJ latent) (JJ transcriptional) (NNS factors)
                (NP
                  (NP (NN signal) (NN transducer))
                  (CC and)
                  (NP (NN activator)))))
            (PP (IN of)
              (NP
                (NP (NN transcription) (-LRB- -LRB-) (NN STAT) (-RRB- -RRB-) (CD 3))
                (CC and)
                (NP (NN STAT1) (CD -LSB-3) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (PP (IN Upon)
        (NP (NN phosphorylation)))
      (, ,)
      (NP
        (NP
          (NP (NN STAT1))
          (CC and)
          (NP (NN STAT3)))
        (NNS proteins))
      (VP
        (VP (VBP form)
          (NP
            (NP (NNS homodimers))
            (CC or)
            (NP (NNS heterodimers))))
        (, ,)
        (VP
          (ADVP (RB rapidly))
          (VBP translocate)
          (PP (IN into)
            (NP (DT the) (NN nucleus))))
        (, ,)
        (CC and)
        (VP (VB modulate)
          (NP (NN gene) (NN transcription)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Intriguingly))
      (, ,)
      (NP (NN STAT3))
      (VP (VBZ is)
        (ADJP (JJ indispensable)
          (PP (IN for)
            (NP (CC both)
              (NP (JJ IL-10-derived) (JJ anti-inflammatory))
              (CC and)
              (NP (JJ IL-6-derived) (JJ proinflammatory) (NNS responses))
              (NP (NN -LSB-4))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Studies))
        (PP (IN of)
          (NP (JJ cell-type-specific) (JJ STAT3-deficient) (NNS mice))))
      (VP (VBP have)
        (VP (VBN shown)
          (SBAR (IN that)
            (S
              (NP (NN STAT3) (NN activation))
              (VP
                (VP (VBZ is)
                  (ADJP (JJ essential)
                    (PP (IN for)
                      (NP
                        (NP (JJ IL-10-mediated) (JJ anti-inflammatory) (NNS reactions))
                        (PP (IN in)
                          (NP
                            (NP (NNS macrophages))
                            (CC and)
                            (NP (NNS neutrophils) (CD -LSB-5) (-RRB- -RSB-))))))))
                (, ,)
                (CC but)
                (VP (VBZ is)
                  (ADJP (JJ responsible)
                    (PP (IN for)
                      (NP
                        (NP (JJ IL-6-mediated) (NN prevention))
                        (PP (IN of)
                          (NP (NN apoptosis)))
                        (PP (IN in)
                          (NP (NN T) (NNS cells) (CD -LSB-6) (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (DT The) (NN suppressor))
          (PP (IN of)
            (NP (NN cytokine) (NN signaling) (-LRB- -LRB-) (NN SOCS) (-RRB- -RRB-))))
        (NNS proteins))
      (VP (VBP have)
        (VP (VBN been)
          (VP (VBN identified)
            (PP (IN as)
              (NP
                (NP (DT a) (NN family))
                (PP (IN of)
                  (NP
                    (NP (JJ endogenous) (NN JAK) (NN kinase) (NNS inhibitors))
                    (SBAR
                      (WHNP (WDT that))
                      (S
                        (VP (MD can)
                          (VP (VB act)
                            (PP (IN in)
                              (NP (JJ classic) (NN feedback) (NN inhibition) (NNS loops)))))))))))))))
    (, ,)
    (CC but)
    (S
      (NP
        (NP (PRP$ their) (NNS roles))
        (PP (IN as)
          (NP
            (NP (DT the) (NNS mediators))
            (PP (IN of)
              (NP
                (NP (NN crosstalk) (NN inhibition))
                (PP (IN by)
                  (NP (JJ opposing) (NN cytokine) (NN signaling) (NNS pathways))))))))
      (VP (VBP have)
        (VP (VBN been)
          (VP (VBN clarified)
            (S
              (NP (NN -LSB-7))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Recent) (NNS studies))
      (VP (VBP indicate)
        (SBAR
          (SBAR (IN that)
            (S
              (NP (NN SOCS3))
              (VP (VBZ plays)
                (NP (DT a) (JJ key) (NN role))
                (PP (IN in)
                  (S
                    (VP (VBG regulating)
                      (NP
                        (NP (DT the) (JJ divergent) (NN action))
                        (PP (IN of)
                          (NP
                            (NP (NN IL-10))
                            (CC and)
                            (NP (NN IL-6))))))))
                (, ,)
                (PP (IN by)
                  (S
                    (ADVP (RB specifically))
                    (VP (VBG blocking)
                      (NP
                        (NP (NN STAT3) (NN activation))
                        (VP (VBN induced)
                          (PP (IN by)
                            (NP (NN IL-6)))))))))))
          (CONJP (CC but)
            (RB not))
          (SBAR (IN that)
            (S
              (VP (VBN induced)
                (PP (IN by)
                  (NP (NN IL-10) (NN -LSB-8,9) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ synovial) (NN membrane))
        (PP (IN of)
          (NP
            (NP (JJ rheumatoid) (NN arthritis))
            (PRN (-LRB- -LRB-)
              (NP (NN RA))
              (-RRB- -RRB-)))))
      (VP (VBZ is)
        (VP (VBN characterized)
          (PP (IN by)
            (NP
              (NP (DT an) (NN infiltrate))
              (PP (IN of)
                (NP
                  (NP (DT a) (NN variety))
                  (PP (IN of)
                    (NP
                      (NP (JJ inflammatory) (NNS cells))
                      (, ,)
                      (PP (JJ such) (IN as)
                        (NP
                          (NP (NNS lymphocytes))
                          (, ,)
                          (NP (NNS macrophages))
                          (, ,)
                          (CC and)
                          (NP (JJ dendritic) (NNS cells))))
                      (, ,)))))
              (PP
                (ADVP (RB together))
                (IN with)
                (NP
                  (NP (NN proliferation))
                  (PP (IN of)
                    (NP (JJ synovial) (JJ fibroblast-like) (NNS cells))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (JJ Numerous) (NNS cytokines))
        (VP (VBP are)
          (ADJP (JJ overproduced)
            (PP (IN in)
              (NP (DT the) (JJ inflamed) (NN joint))))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (NNS macrophages))
          (CC and)
          (NP (JJ synovial) (NNS fibroblasts)))
        (VP (VBP are)
          (NP
            (NP (DT an) (JJ important) (NN source))
            (PP (IN of)
              (NP (JJ proinflammatory) (NNS cytokines)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP
            (NP (NN Tumor) (NN necrosis) (NN factor) (NN alpha))
            (PRN (-LRB- -LRB-)
              (NP (NN TNF-α))
              (-RRB- -RRB-)))
          (CC and)
          (NP
            (NP (NN IL-1))
            (, ,)
            (NP (CD two) (JJ major) (NN macrophage) (NNS products))
            (, ,)))
        (VP (VBP are)
          (ADJP (JJ crucial)
            (PP (IN in)
              (NP
                (NP (DT the) (NN process))
                (PP (IN of)
                  (NP
                    (NP (JJ chronic) (NN inflammation))
                    (CC and)
                    (NP (NN joint) (NN destruction)))))))))
      (, ,)
      (CC and)
      (S
        (NP (PRP they))
        (VP (VBP give)
          (NP (NN rise))
          (PP (TO to)
            (NP
              (NP (NN effector) (NNS components))
              (, ,)
              (PP (VBG including)
                (NP
                  (NP (JJ other) (JJ inflammatory) (NNS cytokines))
                  (, ,)
                  (NP (NNS chemokines))
                  (, ,)
                  (NP (NN growth) (NNS factors))
                  (, ,)
                  (NP (NN matrix) (NNS proteases))
                  (, ,)
                  (NP (JJ nitric) (NN oxide))
                  (, ,)
                  (CC and)
                  (NP (JJ reactive) (NN oxygen) (NNS species) (CD -LSB-10))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN IL-6))
        (VP (VBZ is)
          (NP
            (NP (DT a) (JJ pleiotropic) (NN cytokine))
            (VP (VBN produced)
              (ADVP (RB substantially))
              (PP (IN by)
                (NP (VBN activated) (NNS fibroblasts)))))))
      (, ,)
      (CC and)
      (S
        (NP (PRP$ its) (JJ proinflammatory) (NNS actions))
        (VP (VBP include)
          (S
            (VP (VBG simulating)
              (NP
                (NP (DT the) (JJ acute-phase) (NN response))
                (, ,)
                (NP
                  (NP (NN B-cell) (NN maturation))
                  (PP (IN into)
                    (NP
                      (NP (NN plasma) (NNS cells))
                      (, ,)
                      (NP (NN T-cell) (NNS functions)))))
                (, ,)
                (CC and)
                (NP (JJ hematopoietic) (NN precursor) (NN cell) (NN differentiation) (CD -LSB-11))))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP
        (NP (JJ anti-inflammatory) (NNS cytokines))
        (CC and)
        (NP (NN cytokine) (NNS inhibitors)))
      (VP (VBP are)
        (ADVP (RB also))
        (ADJP (JJ present)
          (PP (IN in)
            (NP
              (NP (JJ large) (NNS quantities))
              (PP (IN in)
                (NP (NN RA) (NNS joints))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (NN IL-10))
          (, ,)
          (VP (VBN produced)
            (PP
              (PP (IN by)
                (NP (NNS macrophages)))
              (CC and)
              (ADVP (RB partly))
              (PP (IN by)
                (NP
                  (NP (NN T) (NNS cells))
                  (PP (IN in)
                    (NP
                      (NP (DT the) (JJ synovial) (NN tissue))
                      (PRN (-LRB- -LRB-)
                        (NP (JJ ST))
                        (-RRB- -RRB-))))))))
          (, ,))
        (VP (VBZ is)
          (ADVP (RB best))
          (VP (VBN known)
            (PP (IN as)
              (NP
                (NP (DT a) (JJ negative) (NN regulator))
                (PP (IN for)
                  (NP (NN macrophage)
                    (CC and)
                    (NN Th1) (NNS cells))))))))
      (, ,)
      (CC but)
      (S
        (NP (DT the) (NN expression) (NN level))
        (VP (VBZ is)
          (ADJP (JJ insufficient)
            (S
              (VP (TO to)
                (VP (VB counterbalance)
                  (NP
                    (NP (DT the) (NN cascade))
                    (PP (IN of)
                      (NP (JJ proinflammatory) (NNS events) (CD -LSB-12) (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP
        (NP (DT the) (JJ anti-inflammatory) (NN action))
        (PP (IN of)
          (NP (NN IL-10))))
      (VP (VBZ appears)
        (S
          (VP (TO to)
            (VP (VB be)
              (VP (VBN modulated)
                (PP (IN at)
                  (NP
                    (NP (DT the) (NN level))
                    (PP (IN of)
                      (NP (NN signal) (NN transduction)))))
                (PP (IN during)
                  (NP (JJ chronic) (NN inflammation)))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-10) (NN signaling))
      (VP (VBZ is)
        (VP (VBN impaired)
          (PP (IN in)
            (NP (NNS macrophages)))
          (PP (IN upon)
            (NP
              (NP (JJ chronic) (NN exposure))
              (PP (TO to)
                (NP
                  (NP (JJ proinflammatory) (NNS cytokines))
                  (PP (JJ such) (IN as)
                    (NP
                      (NP (NN TNF-α))
                      (CC and)
                      (NP
                        (NP
                          (NP (NN IL-1))
                          (CC and)
                          (NP (JJ immune) (NNS complexes)))
                        (CD -LSB-13,14) (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Cell) (NN surface) (NN expression))
        (PP (IN of)
          (NP (NN IL-10R1))))
      (VP (VBZ is)
        (VP (VBN decreased)
          (PP (IN in)
            (NP
              (NP (JJ synovial) (NN fluid) (JJ dendritic) (NNS cells))
              (ADJP (JJ due)
                (PP (TO to)
                  (NP
                    (NP (DT the) (NN presence))
                    (PP (IN of)
                      (NP
                        (NP (NN TNF-α))
                        (, ,)
                        (NP (NN IL-1))
                        (, ,)
                        (CC and)
                        (NP (NN granulocyte–macrophage) (JJ colony-stimulating) (NN factor) (CD -LSB-15))
                        (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ CD4+) (NN T) (NNS cells))
      (VP (MD may)
        (VP (VB be)
          (VP (VBN activated)
            (PP (IN by)
              (NP (JJ arthritogenic) (NNS antigens)))
            (, ,)
            (PP (IN in)
              (NP
                (NP (NN conjunction))
                (PP (IN with)
                  (NP (JJ CD28-mediated) (NN costimulatory) (NN signaling)))))
            (, ,)
            (PP (IN in)
              (NP (NN RA)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN significance))
        (PP (IN of)
          (NP (DT this) (JJ autoimmune) (NN process))))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN supported)
            (PP
              (PP (IN by)
                (NP
                  (NP (DT the) (NN linkage))
                  (PP (IN of)
                    (NP
                      (NP (DT the)
                        (NP (NN MHC) (NN class) (CD II))
                        (NNS antigens))
                      (NP
                        (NP (NN HLA-DRB1) (NN *) (CD 0404))
                        (CC and)
                        (NP (NN HLA-DRB1) (NN *) (CD 0401)))))
                  (PP (IN with)
                    (NP
                      (NP (NN disease) (NN susceptibility))
                      (CC and)
                      (NP (NN severity) (CD -LSB-16,17) (-RRB- -RSB-))))))
              (, ,)
              (CC and)
              (PP (IN by)
                (NP
                  (NP
                    (NP (DT the) (JJ high-level) (NN expression))
                    (PP (IN of)
                      (NP (NN MHC) (NN class) (CD II) (NNS molecules))))
                  (CC and)
                  (NP
                    (NP (DT both) (NN CD28) (NNS ligands))
                    (, ,)
                    (NP
                      (NP (NN CD80))
                      (CC and)
                      (NP (NN CD86)))
                    (, ,))))
              (PP (IN in)
                (NP (DT the) (JJ inflamed) (JJ ST) (NN -LSB-18-20)))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (VBG continuing) (NN emergence))
        (PP (IN of)
          (NP (VBN activated) (JJ CD4+) (NN T) (NNS cells))))
      (, ,)
      (PP
        (ADVP (RB even))
        (IN though)
        (NP
          (NP (JJ few))
          (PP (IN in)
            (NP (NN number)))))
      (, ,)
      (VP (MD may)
        (VP (VB be)
          (ADJP (JJ crucial)
            (PP (IN in)
              (S
                (VP (VBG sustaining)
                  (NP
                    (NP
                      (NP (DT the) (NN activation))
                      (PP (IN of)
                        (NP
                          (NP (NNS macrophages))
                          (CC and)
                          (NP (JJ synovial) (NNS fibroblasts))))
                      (PP (IN through)
                        (NP
                          (NP (NN cell) (NN surface) (NN signaling))
                          (PP (IN by)
                            (NP
                              (NP (NNS means))
                              (PP (IN of)
                                (NP
                                  (NP (NN cell) (NN surface) (NN CD69))
                                  (CC and)
                                  (NP (NN CD11)))))))))
                    (, ,)
                    (CONJP (RB as) (RB well) (IN as))
                    (NP
                      (NP (DT the) (NN release))
                      (PP (IN of)
                        (NP
                          (NP (JJ proinflammatory) (NN Th1) (NNS cytokines))
                          (PP (JJ such) (IN as)
                            (NP
                              (NP
                                (NP
                                  (NP (NN interferon) (NN gamma))
                                  (PRN (-LRB- -LRB-)
                                    (NP (NN IFN))
                                    (-RRB- -RRB-)))
                                (NN -γ))
                              (CC and)
                              (NP (NN IL-17) (NN -LSB-21,22)))))))))
                (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP (JJ CD4+) (NN T) (NNS cells))
      (VP (MD could)
        (VP (VB stimulate)
          (NP
            (NP (NN B-cell) (NN production))
            (PP (IN of)
              (NP
                (NP (NNS autoantibodies))
                (PP (JJ such) (IN as)
                  (NP
                    (NP (JJ rheumatoid) (NN factor))
                    (CC and)
                    (NP (JJ osteoclast-mediated) (NN bone) (NN destruction))))))))))
    (. .)))

(
  (S
    (NP
      (NP (PRP$ Their) (JJ obligatory) (NN role))
      (PP (IN in)
        (NP (NN RA) (NN synovitis))))
    (VP (VBD was)
      (ADVP (RB recently))
      (VP (VBD proved)
        (PP (IN by)
          (NP
            (NP (JJ successful) (NN treatment))
            (PP (IN of)
              (NP (JJ active) (NN disease)))))
        (PP (IN by)
          (NP
            (NP (JJ selective) (NN inhibition))
            (PP (IN of)
              (NP (NN T-cell) (NN activation)))
            (PP (IN with)
              (NP
                (NP (NN fusion) (NN protein))
                (PP (IN of)
                  (NP
                    (NP (JJ cytotoxic) (JJ T-cell-associated) (NN antigen))
                    (NP (CD 4) (-LRB- -LRB-) (CD CD152) (-RRB- -RRB-) (NN -IgG))
                    (, ,)
                    (SBAR
                      (WHNP (WDT which))
                      (S
                        (VP (MD can)
                          (VP (VB block)
                            (NP
                              (NP (DT the) (NN engagement))
                              (PP (IN of)
                                (NP (NN CD28)))
                              (PP (IN on)
                                (NP (NN T) (NNS cells))))
                            (PP (IN by)
                              (S
                                (VP (VBG binding)
                                  (PP (TO to)
                                    (NP
                                      (NP (NN CD80))
                                      (CC and)
                                      (NP (NN CD86))))
                                  (PP (IN with)
                                    (NP (JJ high) (NN avidity) (CD -LSB-23) (-RRB- -RSB-))))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-10))
      (ADVP (RB efficiently))
      (VP (VBZ blocks)
        (NP (DT the) (JJ antigen-specific) (NN T-cell) (NN cytokine) (NN response))
        (PP
          (PP (IN by)
            (S
              (VP (VBG inhibiting)
                (NP (DT the) (NN CD28) (NN signaling) (NN pathway) (CD -LSB-24)))
              (-RRB- -RSB-)))
          (, ,)
          (CONJP (RB as) (RB well) (IN as))
          (ADVP (RB indirectly))
          (PP (IN by)
            (S
              (VP (VBG downregulating)
                (NP
                  (NP (DT the) (NN function))
                  (PP (IN of)
                    (NP (JJ antigen-presenting) (NNS cells))))))))))
    (. .)))

(
  (S
    (S
      (VP (TO To)
        (VP (VB elucidate)
          (NP
            (NP (DT the) (NN resistance))
            (PP (IN of)
              (NP (JJ CD4+) (NN T) (NNS cells)))
            (PP (TO to)
              (NP
                (NP (DT this) (JJ direct) (NN inhibition))
                (PP (IN in)
                  (NP (NN RA)))))))))
    (, ,)
    (NP (PRP we))
    (VP (VBD investigated)
      (NP
        (NP
          (NP (DT the) (NN production))
          (PP (IN of)
            (NP
              (NP (NN IFN-γ))
              (PP (IN after)
                (NP
                  (NP
                    (NP (NN CD3))
                    (CC and)
                    (NP (NN CD28)))
                  (NN costimulation)))))
          (PP (IN in)
            (NP
              (NP (DT the) (NN presence))
              (PP (IN of)
                (NP (NN IL-10))))))
        (, ,)
        (NP
          (NP (DT the) (NN induction))
          (PP (IN of)
            (NP
              (NP (NN STAT1))
              (CC and)
              (NP (NN STAT3))
              (NP (NN phosphorylation))))
          (PP (IN by)
            (NP (NN IL-10))))
        (, ,)
        (CC and)
        (NP
          (NP (DT the) (NN expression))
          (PP (IN of)
            (NP
              (NP (NN SOCS1))
              (CC and)
              (NP (NN SOCS3))
              (NP (NN mRNA))))
          (PP (IN in)
            (NP
              (NP
                (NP
                  (NP (JJ peripheral) (NN blood))
                  (PRN (-LRB- -LRB-)
                    (NP (NN PB))
                    (-RRB- -RRB-)))
                (JJ CD4+) (NN T) (NNS cells))
              (PP (IN from)
                (NP (NN RA) (NNS patients))))))))
    (. .)))

(
  (S
    (NP
      (NP (NNS Materials))
      (CC and)
      (NP (NNS methods)))))

(
  (S
    (S
      (NP (DT The) (JJ total) (NN patient) (NN population))
      (VP (VBD consisted)
        (PP (IN of)
          (NP
            (NP (CD 32) (NNS patients))
            (PP (IN with)
              (NP (NN RA)))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (CD 25) (NNS women))
                (CC and)
                (NP (CD seven) (NNS men)))
              (: ;)
              (NP (NN mean) (NN ±) (JJ standard) (NN deviation) (NN age))
              (, ,)
              (NP (CD 52.8) (NN ±) (CD 12.4) (NNS years))
              (-RRB- -RRB-))
            (VP (VBN diagnosed)
              (PP (VBG according)
                (PP (TO to)
                  (NP
                    (NP (DT the) (JJ revised) (CD 1987) (NNS criteria))
                    (PP (IN of)
                      (NP
                        (NP (DT the) (NNP American) (NNP College))
                        (PP (IN of)
                          (NP (NN Rheumatology)
                            (PRN (-LRB- -LRB-)
                              (NP
                                (NP (RB formally))
                                (, ,)
                                (NP (DT the)
                                  (NP (NNP American))
                                  (NN Rheumatism) (NN Association)))
                              (-RRB- -RRB-))
                            (CD -LSB-25) (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT All) (NNS patients))
      (VP (VBD were)
        (VP (VBG receiving)
          (NP
            (NP
              (NP (NN prednisolone))
              (PRN (-LRB- -LRB-)
                (NP (NN ≤) (CD 7.5) (NN mg/day))
                (-RRB- -RRB-)))
            (CC and)
            (NP (JJ disease-modifying) (NN antirheumatic) (NNS drugs))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Clinical) (NNS parameters))
        (PP (IN in)
          (NP (DT the) (NN study) (NNS patients))))
      (VP (VBD were)
        (SBAR (IN as)
          (S
            (VP (VBZ follows) (-LRB- -LRB-)
              (NP (NN mean) (NN ±) (JJ standard) (NN deviation))
              (-RRB- -RRB-))))))
    (: :)
    (NP
      (NP (NN erythrocyte) (NN sedimentation) (NN rate))
      (, ,)
      (NP (CD 55.9) (NN ±) (CD 35.4) (NN mm/hour))
      (: ;)
      (NP
        (NP
          (NP
            (NP (NN serum) (JJ C-reactive) (NN protein))
            (PRN (-LRB- -LRB-)
              (NP (NN CRP))
              (-RRB- -RRB-)))
          (NN level))
        (, ,)
        (NP
          (QP (CD 32.0) (CD ±) (CD 32.0))
          (NN mg/l)))
      (: ;)
      (CC and)
      (NP
        (NP (NN IgM) (NN class) (NN rheumatoid) (NN factor) (NN titer))
        (, ,)
        (NP (CD 142) (NN ±) (CD 158) (NN U/ml))))
    (. .)))

(
  (S
    (S
      (NP (NNS Patients))
      (VP (VBD were)
        (VP (VBN divided)
          (PP (IN into)
            (NP
              (NP (CD two) (NNS groups))
              (: :)
              (NP
                (NP (CD 24) (NNS patients))
                (PP (IN with)
                  (NP (JJ active) (NN disease)))
                (, ,)
                (SBAR
                  (WHNP (WP who))
                  (S
                    (VP
                      (VP (VBD had)
                        (NP (JJ multiple) (NN tender)
                          (CC and/or)
                          (JJ swollen) (NNS joints)))
                      (CC and)
                      (VP (VBD elevated)
                        (NP
                          (NP (NN serum) (NN CRP) (NN level))
                          (PRN (-LRB- -LRB-)
                            (NP (NN ≥) (CD 10) (NN mg/l))
                            (-RRB- -RRB-))))))))
              (: ;)
              (CC and)
              (NP
                (NP (CD eight) (NNS patients))
                (PP (IN with)
                  (NP (JJ inactive) (NN disease)))
                (, ,)
                (SBAR
                  (WHNP (WP who))
                  (S
                    (VP (VBD satisfied)
                      (NP
                        (NP
                          (NP
                            (NP (DT the) (NNP American) (NNP College))
                            (PP (IN of)
                              (NP (NN Rheumatology))))
                          (JJ preliminary) (NNS criteria))
                        (PP (IN for)
                          (NP (JJ clinical) (NN remission) (CD -LSB-26)))))
                    (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD Sixteen) (JJ healthy) (NNS volunteers))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (CD 11) (NNS women))
            (CC and)
            (NP (CD five) (NNS men)))
          (: ;)
          (NP (NN age))
          (, ,)
          (NP
            (QP (CD 45.8) (CD ±) (CD 11.2))
            (NNS years))
          (-RRB- -RRB-)))
      (VP (VBD served)
        (PP (IN as)
          (NP (NNS controls)))))
    (. .)))

(
  (S
    (S
      (NP (JJ ST) (NNS samples))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN from)
            (NP
              (NP (CD three) (NN RA) (NNS patients))
              (VP (VBG undergoing)
                (NP (JJ total) (NN knee) (NN replacement))))))))
    (. .)))

(
  (S
    (S
      (NP (DT All) (NNS patients))
      (VP (VBD gave)
        (NP (VBN informed) (NN consent))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Peripheral) (NN blood) (JJ mononuclear) (NNS cells))
        (PRN (-LRB- -LRB-)
          (NP (NN PBMC))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN prepared)
          (PP (IN from)
            (NP (JJ heparinized) (NN blood) (NNS samples)))
          (PP (IN by)
            (NP
              (NP (NN centrifugation))
              (PP (IN over)
                (NP
                  (NP (JJ Ficoll-Hypaque) (NN density) (NNS gradients))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NNP Pharmacia))
                      (, ,)
                      (NP (NNP Uppsala) (, ,) (NNP Sweden)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ CD4+) (NN T) (NNS cells))
      (VP (VBD were)
        (VP (VBN purified)
          (PP (IN from)
            (NP (NN PBMC)))
          (PP (IN by)
            (NP
              (NP (JJ positive) (NN selection))
              (VP (VBG using)
                (NP
                  (NP (JJ anti-CD4) (JJ mAb-coated) (JJ magnetic) (NNS beads))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NNP Miltenyi) (NNP Biotec))
                      (, ,)
                      (NP (NNP Gladbach) (, ,) (NNP Germany)))
                    (-RRB- -RRB-))))))
          (, ,)
          (PP (VBG according)
            (PP (TO to)
              (NP
                (NP (DT the) (NN manufacturer) (POS 's))
                (NNS instructions)))))))
    (. .)))

(
  (S
    (S
      (NP (JJ CD4+) (NN T) (NNS cells))
      (VP (VBD were)
        (VP (VBN isolated)
          (PP (IN from)
            (NP (JJ ST) (NNS samples)))
          (, ,)
          (PP (IN as)
            (NP
              (ADJP (RB previously) (VBN described))
              (NN -LSB-27)))
          (-RRB- -RSB-))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Briefly))
      (, ,)
      (NP (JJ fresh) (JJ ST) (NNS samples))
      (VP (VBD were)
        (ADJP
          (ADJP (JJ fragmented))
          (CC and)
          (ADJP (JJ digested))
          (PP (IN with)
            (NP
              (NP (NN collagenase))
              (CC and)
              (NP (NN DNase))))
          (PP (IN for)
            (NP
              (NP (CD 1) (NN hour))
              (PP (IN at)
                (NP (NN 37°C))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP (VBG removing) (NN tissue) (NN debris)))
      (, ,)
      (NP
        (NP (JJ ST) (NN cell) (NNS suspensions))
        (PP (IN in)
          (NP
            (NP
              (NP (NN culture) (NN medium))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN RPMI) (CD 1640) (NN medium))
                  (: ;)
                  (NP (NN Life) (NNS Technologies))
                  (, ,)
                  (NP (NNP Gaithersburg) (, ,) (NNP MD) (, ,) (NNP USA)))
                (-RRB- -RRB-)))
            (VP (VBN supplemented)
              (PP (IN with)
                (NP
                  (NP (CD 25) (NN mM) (NNS HEPES))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 2) (NN mM) (NN L-glutamine))
                    (, ,)
                    (NP
                      (NP
                        (ADJP (CD 2) (NN %))
                        (JJ nonessential) (NN amino) (NNS acids))
                      (, ,)
                      (NP (CD 100) (NN IU/ml) (NN penicillin))
                      (, ,)
                      (CC and)
                      (NP (CD 100) (NN mg/ml) (NN streptomycin)))
                    (: ;)
                    (NP (NN Life) (NNS Technologies))
                    (-RRB- -RRB-))))
              (PP (IN with)
                (NP
                  (NP
                    (ADJP (CD 10) (NN %))
                    (JJ heat-inactivated) (NN FCS))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Life) (NNS Technologies))
                    (-RRB- -RRB-))))))))
      (VP (VBD were)
        (VP (VBN incubated)
          (PP (IN at)
            (NP
              (NP (NN 37°C))
              (PP (IN in)
                (NP
                  (NP (JJ six-well) (NNS plates))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP Coster))
                    (, ,)
                    (NP (NN Cambridge))
                    (, ,)
                    (NP (NNP MA) (, ,) (NNP USA))
                    (-RRB- -RRB-))))))
          (PP (IN for)
            (NP (CD 45) (NN min))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (JJ Non-adherent) (NNS cells))
        (VP (VBD were)
          (VP (VBN harvested))))
      (CC and)
      (S
        (NP (JJ CD4+) (NN T) (NNS cells))
        (VP (VBD were)
          (VP (VBN purified)
            (PP (IN by)
              (NP (JJ positive) (NN selection))))
          (SBAR (IN as)
            (S
              (ADVP (RB already))
              (VP (VBN described)))))))
    (. .)))

(
  (S
    (S
      (NP
        (ADJP (NN PB) (JJ CD4+))
        (NN T-cell) (NNS populations))
      (VP (VBD were)
        (VP (VBN resuspended)
          (PP (IN at)
            (NP
              (NP (DT a) (NN density))
              (PP (IN of)
                (NP
                  (QP (CD 1) (CD ×) (CD 106))
                  (NNS cells/ml)))))
          (PP (IN in)
            (NP
              (NP (NN culture) (NN medium))
              (PP (IN with)
                (NP
                  (ADJP (CD 10) (NN %))
                  (NN FCS))))))))
    (, ,)
    (CC and)
    (S
      (NP
        (ADJP (CD 0.5) (NN ml))
        (NN cell) (NNS suspensions))
      (VP (VBD were)
        (VP (VBN dispensed)
          (PP (IN into)
            (NP
              (NP (DT the) (NNS wells))
              (PP (IN of)
                (NP
                  (NP
                    (NP (JJ 24-well) (NN microtiter) (NNS plates))
                    (PRN (-LRB- -LRB-)
                      (NP (NNP Coster))
                      (-RRB- -RRB-)))
                  (VP (VBN coated)
                    (PP (IN with)
                      (NP
                        (NP
                          (ADJP (CD 1) (NN μg/ml))
                          (JJ anti-CD3) (NN mAb))
                        (PRN (-LRB- -LRB-)
                          (NP (NNP Immunotech) (, ,) (NNP Marseille) (, ,) (NNP France))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS cells))
      (VP (VBD were)
        (VP (VBN incubated)
          (PP (IN with)
            (NP (CD 1) (NN μg/ml) (JJ anti-CD28) (NN mAb)))
          (PRN (-LRB- -LRB-)
            (NP (NNP Immunotech))
            (-RRB- -RRB-))
          (PP (IN in)
            (NP
              (NP (DT the)
                (NP (NN presence))
                (CC or)
                (NP (NN absence)))
              (PP (IN of)
                (NP
                  (NP (DT the) (VBN indicated) (NNS concentrations))
                  (PP (IN of)
                    (NP (NN IL-10)))))))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NNP Becton) (NNP Dickinson) (, ,) (NNP San) (NNP Jose))
              (, ,)
              (NP (NN CA))
              (, ,)
              (NP (NNP USA)))
            (-RRB- -RRB-))
          (PP (IN at)
            (NP
              (NP (NN 37°C))
              (PP (IN in)
                (NP
                  (NP (DT a) (JJ humidified) (NN atmosphere))
                  (VP (VBG containing)
                    (NP
                      (ADJP (CD 5) (NN %))
                      (NN CO2) (CD -LSB-28) (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN Culture) (NNS supernatants))
        (VP (VBD were)
          (VP (VBN collected)
            (ADVP
              (NP (CD 36) (NNS hours))
              (RB later)))))
      (CC and)
      (S
        (NP (JJ cell-free) (NNS samples))
        (VP (VBD were)
          (VP (VBN stored)
            (PP (IN at)
              (NP (NN -30°C)))
            (PP (IN until)
              (NP (NN cytokine) (NN assay)))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB examine)
            (NP
              (NP (DT the) (NN effect))
              (PP (IN of)
                (NP (NN IL-6)))
              (PP (IN on)
                (NP
                  (NP (NN T-cell) (NN responsiveness))
                  (PP (TO to)
                    (NP (NN IL-10)))))))))
      (, ,)
      (NP
        (NP (JJ CD4+) (NN T) (NNS cells))
        (PP (IN from)
          (NP (JJ healthy) (NNS controls))))
      (VP (VBD were)
        (VP (VBN incubated)
          (PP (IN in)
            (NP (NN culture) (NN medium)))
          (PP (IN with)
            (NP
              (NP
                (ADJP (CD 10) (NN %))
                (NN FCS))
              (PP (IN in)
                (NP
                  (NP (DT the)
                    (NP (NN presence))
                    (CC or)
                    (NP (NN absence)))
                  (PP (IN of)
                    (NP
                      (ADJP (CD 10) (NN ng/ml))
                      (NN IL-6)))))))
          (PRN (-LRB- -LRB-)
            (NP (NNP Becton) (NNP Dickinson))
            (-RRB- -RRB-))
          (PP (IN for)
            (NP (CD 36) (NNS hours))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Cells))
      (VP (VBD were)
        (ADVP (RB then))
        (VP (VBN stimulated)
          (PP (IN for)
            (NP
              (NP (CD 36) (NNS hours))
              (PP (IN with)
                (NP
                  (NP (JJ anti-CD3) (NN mAb))
                  (CC and)
                  (NP (JJ anti-CD28) (NN mAb))))))
          (PP (IN in)
            (NP
              (NP (DT the)
                (NP (NN presence))
                (CC or)
                (NP (NN absence)))
              (PP (IN of)
                (NP
                  (ADJP (CD 1) (NN ng/ml))
                  (NN IL-10))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Culture) (NNS supernatants))
      (VP (VBD were)
        (VP (VBN measured)
          (PP (IN for)
            (NP (JJ IFN-γ) (NNS concentrations))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (NN sample))
        (PP (IN of)
          (NP
            (NP (CD 5) (NN ×) (CD 105) (NNS cells))
            (PP (IN of)
              (NP (NN PBMC))))))
      (VP (VBD was)
        (VP (VBN resuspended)
          (PP (IN in)
            (NP
              (NP (NNS PBS))
              (PP (IN with)
                (NP
                  (ADJP (CD 1) (NN %))
                  (NN FCS))))))))
    (. .)))

(
  (S
    (NP (NN PBMC))
    (VP (VBD were)
      (VP (VBN incubated)
        (PP
          (PP (IN with)
            (NP
              (NP (JJ saturating) (NNS concentrations))
              (PP (IN of)
                (NP
                  (NP (JJ anti-IL-10R1) (NN mAb))
                  (PRN (-LRB- -LRB-)
                    (NP (NN IgG1))
                    (: ;)
                    (NP (NN R&D) (NNS systems))
                    (, ,)
                    (NP
                      (NP (NNP Minneapolis))
                      (, ,)
                      (NP (NN MN))
                      (, ,)
                      (NP (NNP USA)))
                    (-RRB- -RRB-))))))
          (CC or)
          (PP (IN with)
            (NP
              (NP
                (NP (JJ isotype-matched) (NN control) (NN mAb))
                (PRN (-LRB- -LRB-)
                  (NP (NN Immunotech))
                  (-RRB- -RRB-)))
              (, ,)
              (VP (VBN followed)
                (PP (IN by)
                  (NP
                    (NP (NN incubation))
                    (PP (IN with)
                      (NP
                        (NP (JJ FITC-conjugated) (NN goat) (JJ anti-mouse) (NN IgG1) (JJ polyclonal) (NN antibody))
                        (PRN (-LRB- -LRB-)
                          (NP (NNP Santa) (NNP Cruz) (NNP Biotechnologies) (, ,) (NNP Santa) (NNP Cruz) (, ,)
                            (NP (NN CA))
                            (, ,)
                            (NP (NNP USA)))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Cells))
      (VP (VBD were)
        (ADVP (RB then))
        (VP (VBN incubated)
          (PP (IN with)
            (NP
              (NP (JJ phycoerythrin-conjugated) (JJ anti-CD4) (NN mAb))
              (PRN (-LRB- -LRB-)
                (NP (NNP Becton) (NNP Dickinson))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Cells))
      (VP (VBD were)
        (VP (VBN washed)
          (ADVP (RB well))
          (PP (IN with)
            (NP
              (NP
                (ADJP (CD 1) (NN %))
                (NN FCS/PBS))
              (PP (IN between)
                (NP (NNS incubations))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Analysis))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN on)
            (NP
              (NP (DT a) (NN FACScan) (NN flow) (NN cytometer))
              (PRN (-LRB- -LRB-)
                (NP (NNP Becton) (NNP Dickinson))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Concentrations))
        (PP (IN of)
          (NP
            (NP (NN IFN-γ))
            (CC and)
            (NP (NN IL-2))))
        (PP (IN in)
          (NP
            (NP (NN culture) (NNS supernatants))
            (PP (IN of)
              (NP (JJ CD4+) (NN T) (NNS cells))))))
      (VP (VBD were)
        (VP (VBN measured)
          (PP (IN in)
            (NP (NN duplicate)))
          (PP (IN by)
            (NP
              (NP (DT the) (JJ quantitative) (NN sandwich) (NN ELISA))
              (VP (VBG using)
                (NP (JJ cytokine-specific) (NN capture)))))
          (PP (IN with)
            (NP
              (NP (VBN biotinylated) (NN detection) (NN mAb))
              (CC and)
              (NP
                (NP (JJ recombinant) (NN cytokine) (NNS proteins))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN all))
                    (PP (IN from)
                      (NP (NNP Becton) (NNP Dickinson))))
                  (-RRB- -RRB-)))))
          (, ,)
          (PP (VBG according)
            (PP (TO to)
              (NP
                (NP (DT the) (NN manufacturer) (POS 's))
                (NN protocol)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN detection) (NNS limits))
        (PP (IN for)
          (NP
            (NP (NN IFN-γ))
            (CC and)
            (NP (NN IL-2)))))
      (VP (VBD were)
        (NP (CD 15) (NN pg/ml))))
    (. .)))

(
  (S
    (S
      (NP (JJ Total) (JJ cellular) (NN RNA))
      (VP (VBD was)
        (VP (VBN extracted)
          (PP (IN from)
            (NP
              (NP (NN PB) (JJ CD4+) (NN T) (NNS cells))
              (VP (VBG using)
                (NP
                  (NP (DT an) (NN RNA) (NN isolation) (NN kit))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP
                        (NP (NNP RNeasy) (NNP Mini))
                        (NP (NN kit)))
                      (: ;)
                      (NP (NN Qiagen))
                      (, ,)
                      (NP (NNP Valencia))
                      (, ,)
                      (NP (NN CA) (, ,) (NNP USA)))
                    (-RRB- -RRB-))))))
          (, ,)
          (PP (VBG according)
            (PP (TO to)
              (NP
                (NP (DT the) (NN manufacturer) (POS 's))
                (NNS instructions)))))))
    (. .)))

(
  (S
    (S
      (NP (NN cDNA))
      (VP (VBD was)
        (VP (VBN synthesized)
          (PP (IN from)
            (NP
              (NP (JJ total) (NN RNA))
              (PP (IN with)
                (NP
                  (NP
                    (NP (NN Molony) (JJ murine) (NN leukemia) (NN virus) (JJ reverse) (NN transcriptase))
                    (-LRB- -LRB-)
                    (NP
                      (ADJP
                        (NP (PRP US))
                        (JJ Biochemical))
                      (, ,) (NNP Cleveland) (, ,) (NN OH) (, ,) (NNP USA))
                    (-RRB- -RRB-)
                    (CC and)
                    (JJ oligo-) (-LRB- -LRB-) (NN dT) (-RRB- -RRB-) (CD 15) (NNS primers))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NNP Promega) (, ,) (NNP Madison) (, ,) (NNP WI))
                      (, ,)
                      (NP (NNP USA)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Real-time) (NN PCR))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN with)
            (NP
              (NP
                (NP (DT the) (NN LightCycler) (NN Instrument))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN Roche) (NN Diagnostics))
                    (, ,)
                    (NP (NNP Penzberg) (, ,) (NNP Germany)))
                  (-RRB- -RRB-)))
              (PP (IN in)
                (NP (NN glass) (NNS capillaries))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN reaction) (NN mix))
        (VP (VBG containing)
          (NP
            (NP
              (NP
                (NP (NN Taq) (NN DNA) (NN polymerase))
                (CC and)
                (NP (NN DNA) (JJ double-strand-specific) (NN SYBR) (NN Green) (NN I) (CD dye)))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN Lightcycler) (NN FastStart) (NN DNA) (NN Master) (NN SYBR) (NN Green) (NN I))
                  (: ;)
                  (NP (NN Roche) (NN Diagnostics)))
                (-RRB- -RRB-)))
            (CC and)
            (NP (JJ specific) (NNS primers)))))
      (VP (VBD were)
        (VP (VBN added)
          (PP (TO to)
            (NP (NN cDNA) (NNS dilutions))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN cDNA) (NNS samples))
      (VP (VBD were)
        (VP (VBN denatured)
          (PP (IN at)
            (NP
              (NP (NN 95°) (NN C))
              (PP (IN for)
                (NP (CD 10) (NN min))))))
        (, ,)
        (CC and)
        (VP (VBD were)
          (ADVP (RB then))
          (VP (VBN amplified)
            (PP (IN for)
              (NP
                (NP (CD 40–50) (NNS cycles))
                (: :)
                (PP
                  (PP
                    (PP (IN at)
                      (NP
                        (NP
                          (NP
                            (NP
                              (NP
                                (NP (NN 95°) (NN C))
                                (PRN (-LRB- -LRB-)
                                  (NP (CD 10) (NN s))
                                  (-RRB- -RRB-)))
                              (, ,)
                              (PP (IN at)
                                (NP
                                  (NP (NN 65°) (NN C))
                                  (PRN (-LRB- -LRB-)
                                    (NP (CD 15) (NN s))
                                    (-RRB- -RRB-))))
                              (, ,))
                            (CC and)
                            (NP (NN 72°) (NN C)))
                          (PRN (-LRB- -LRB-)
                            (NP (CD 22) (NNS s))
                            (-RRB- -RRB-)))
                        (PP (IN for)
                          (NP
                            (NP (NN β-actin) (: ;))
                            (PP (IN at)
                              (NP
                                (NP (NN 95°) (NN C))
                                (PRN (-LRB- -LRB-)
                                  (NP (CD 10) (NN s))
                                  (-RRB- -RRB-))))))))
                    (, ,)
                    (PP (IN at)
                      (NP
                        (NP (NN 62°) (NN C))
                        (PRN (-LRB- -LRB-)
                          (NP (CD 15) (NNS s))
                          (-RRB- -RRB-))))
                    (, ,)
                    (CC and)
                    (PP (IN at)
                      (NP
                        (NP
                          (NP (NN 72°) (NN C))
                          (PRN (-LRB- -LRB-)
                            (NP (CD 10) (NN s))
                            (-RRB- -RRB-)))
                        (PP (IN for)
                          (NP (NN SOCS1)))))
                    (: ;)
                    (CC and)
                    (PP (IN at)
                      (NP
                        (NP (NN 96°) (NN C))
                        (PRN (-LRB- -LRB-)
                          (NP (CD 10) (NN s))
                          (-RRB- -RRB-)))))
                  (, ,)
                  (PP (IN at)
                    (NP
                      (NP (NN 68°) (NN C))
                      (PRN (-LRB- -LRB-)
                        (NP (CD 15) (NNS s))
                        (-RRB- -RRB-))))
                  (, ,)
                  (CC and)
                  (PP (IN at)
                    (NP
                      (NP
                        (NP (NN 72°) (NN C))
                        (PRN (-LRB- -LRB-)
                          (NP (CD 15) (NN s))
                          (-RRB- -RRB-)))
                      (PP (IN for)
                        (NP (NN SOCS3))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (NN Amplification) (NNS curves))
          (PP (IN of)
            (NP
              (NP (DT the) (NN fluorescence) (NNS values))
              (CC versus)
              (NP (NN cycle) (NN number)))))
        (VP (VBD were)
          (VP (VBN obtained))))
      (, ,)
      (CC and)
      (S
        (NP (DT a) (NN melting) (NN curve) (NN analysis))
        (VP (VBD was)
          (ADVP (RB then))
          (VP (VBN performed)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS levels))
        (PP (IN of)
          (NP
            (NP (NN SOCS1))
            (CC and)
            (NP (NN SOCS3))
            (NP (NN expression)))))
      (VP (VBD were)
        (VP (VBN determined)
          (PP (IN by)
            (S
              (VP (VBG normalizing)
                (PP (JJ relative) (TO to)
                  (NP (NN β-actin) (NN expression)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The)
        (ADJP
          (ADJP (JJ forward))
          (CC and)
          (ADJP (JJ reverse)))
        (NNS primers))
      (VP (VBD were)
        (PP (IN as)
          (NP
            (NP (VBZ follows))
            (: :)
            (PP
              (PP (IN for)
                (NP
                  (NP (NN β-actin))
                  (, ,)
                  (NP
                    (NP (NN 5'-GTGGGGCGCCCCAGGCACCA-3) (POS '))
                    (CC and)
                    (NP (NN 5'-CTCCTTAATGTCACGCACGATTTC-3) (POS ')))))
              (: ;)
              (PP (IN for)
                (NP
                  (NP (NN SOCS1))
                  (, ,)
                  (NP
                    (NP (NN 5'-AGACCCCTTCTCACCTCTTG-3) (POS '))
                    (CC and)
                    (NP (NN 5'-GCACAGCAGAAAAATAAAGC-3) (POS ')))))
              (: ;)
              (CC and)
              (PP (IN for)
                (NP
                  (NP (NN SOCS3))
                  (, ,)
                  (NP
                    (NP (NN 5'-CCCGCCGGCACCTTTCTG-3) (POS '))
                    (CC and)
                    (NP (NN 5'-AGGGGCCGGCTCAACACC-3) (POS '))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ CD4+) (NN T) (NNS cells))
      (VP (VBD were)
        (VP (VBN stimulated)
          (PP (IN for)
            (NP (CD 20) (NN min)))
          (PP (IN by)
            (NP
              (NP (DT the) (VBN indicated) (NNS concentrations))
              (PP (IN of)
                (NP
                  (NP (NN IL-10))
                  (CC and)
                  (NP (NN IL-6))))))
          (PP (IN at)
            (NP
              (NP (DT a) (NN density))
              (PP (IN of)
                (NP
                  (NP (CD 5) (NN ×) (CD 105) (NNS cells))
                  (PP (IN in)
                    (NP
                      (NP
                        (ADJP (CD 0.5) (NN ml))
                        (NN culture) (NN medium))
                      (PP (IN with)
                        (NP
                          (ADJP (CD 10) (NN %))
                          (NN FCS))))))))))))
    (. .)))

(
  (S
    (S
      (VP (TO To)
        (VP (VB examine)
          (NP
            (NP (DT the) (NN effect))
            (PP (IN of)
              (NP (NN serum) (NN IL-6)))
            (PP (IN on)
              (NP (NN STAT) (NN phosphorylation)))))))
    (, ,)
    (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells))
    (VP (VBD were)
      (VP (VBN stimulated)
        (PP (IN for)
          (NP (CD 20) (NN min)))
        (PP (IN with)
          (NP
            (ADJP (CD 30) (NN %))
            (JJ active) (NN RA) (NN serum)))
        (PP (IN in)
          (NP
            (NP (NN culture) (NN medium))
            (PP (IN with)
              (NP
                (NP (CD 40) (NNS μg/ml))
                (VP (VBG neutralizing)
                  (NP
                    (NP
                      (NP (NN goat) (JJ anti-IL-6) (JJ polyclonal) (NN antibody))
                      (PRN (-LRB- -LRB-)
                        (NP
                          (NP (NN IgG))
                          (: ;)
                          (NP (NNP Techne) (, ,) (NNP Princeton) (, ,) (NNP NJ))
                          (, ,)
                          (NP (NN USA)))
                        (-RRB- -RRB-)))
                    (CC or)
                    (NP
                      (NP (NN control) (NN goat) (NN IgG))
                      (PRN (-LRB- -LRB-)
                        (NP (NN Techne))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Whole) (NN cell) (NNS lysates))
      (VP (VBD were)
        (VP (VBN prepared)
          (PP (IN by)
            (S
              (VP (VBG placing)
                (NP (NNS cells))
                (PP (IN in)
                  (NP
                    (NP (CD 100) (NN μl) (NN SDS) (VBG lysing) (NN buffer))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 62.5) (NN mM) (NN Tris–HCl) (NN -LSB-pH) (CD 6.8))
                      (-RRB- -RSB-))))
                (PRN (, ,)
                  (NP
                    (NP
                      (ADJP (CD 2) (NN %))
                      (NN SDS))
                    (, ,)
                    (NP
                      (ADJP (CD 10) (NN %))
                      (NN glycerol))
                    (, ,)
                    (NP
                      (ADJP (CD 50) (NN mM))
                      (NN dithiothreitol)))
                  (, ,)
                  (NP
                    (NP (CD 0.1) (NN %))
                    (ADJP (NN bromphenol) (JJ blue)))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (QP (RB Then) (CD 20))
          (JJ μl) (NN protein) (NNS samples))
        (VP
          (VP (VBD were)
            (VP (VBN fractionated)
              (PP (IN on)
                (NP
                  (ADJP (CD 10) (NN %))
                  (NN SDS-polyacrylamide) (NNS gels)))))
          (CC and)
          (VP (VBD were)
            (VP (VBN transferred)
              (PP (TO to)
                (NP (NN nitrocellulose) (NNS membranes)))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NNP Amersham) (, ,) (NNP Buckinghamshire))
                  (, ,)
                  (NP (NNP UK)))
                (-RRB- -RRB-))))))
      (, ,)
      (CC and)
      (S
        (NP (DT the) (NN membrane))
        (VP (VBD was)
          (VP (VBN blocked)
            (PP (IN with)
              (NP
                (NP
                  (ADJP (CD 5) (NN %))
                  (NN skim) (NN milk))
                (PP (IN in)
                  (NP
                    (NP (JJ Tris-buffered) (NN saline))
                    (PP (IN with)
                      (NP
                        (ADJP (CD 0.1) (NN %))
                        (NNP Tween) (CD 20)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Tyrosine) (NN phosphorylation))
        (PP (IN of)
          (NP
            (NP (NN STAT1))
            (CC and)
            (NP (NN STAT3)))))
      (VP (VBD was)
        (VP (VBN detected)
          (S
            (VP (VBG using)
              (NP
                (NP
                  (NP (JJ commercial) (JJ available) (NNS kits))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN Cell) (NN Signaling) (NN Technology))
                      (, ,)
                      (NP (NNP Beverly) (, ,) (NNP MA))
                      (, ,)
                      (NP (NN USA)))
                    (-RRB- -RRB-)))
                (VP (VBG according)
                  (PP (TO to)
                    (NP
                      (NP (DT the) (NN manufacturer) (POS 's))
                      (NNS instructions))))))))))
    (. .)))

(
  (S
    (ADVP (RB Briefly))
    (, ,)
    (NP (DT the) (NN membrane))
    (VP (VBD was)
      (VP (VBN incubated)
        (PP (IN with)
          (NP
            (NP
              (NP
                (NP (DT the) (NNS antibodies))
                (PRN (-LRB- -LRB-)
                  (NP (NN rabbit) (NN IgG))
                  (-RRB- -RRB-)))
              (NN anti-STAT1) (NN antibody))
            (, ,)
            (NP
              (NP
                (NP (JJ anti-phosphorylated) (NN tyrosine) (CD 701))
                (PP (IN of)
                  (NP (NN STAT1))))
              (NN antibody))
            (, ,)
            (NP (JJ anti-STAT3) (NN antibody))
            (, ,)
            (CC and)
            (NP
              (NP (JJ anti-phosphorylated) (NN tyrosine) (NN 705))
              (PP (IN of)
                (NP (NN STAT3) (NN antibody))))))
        (, ,)
        (S
          (VP (VBN diluted)
            (SBAR (IN as)
              (S
                (VP (VBN recommended)
                  (PP (IN at)
                    (NP
                      (NP (NN 1/2000))
                      (PP (IN with)
                        (NP
                          (NP (JJ Tris-buffered) (NN saline))
                          (PP (IN with)
                            (NP
                              (ADJP (CD 0.1) (NN %))
                              (NNP Tween) (CD 20)))
                          (PP (IN with)
                            (NP
                              (ADJP (CD 5) (NN %))
                              (NN BSA))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Antibody) (NN binding))
      (VP
        (VP (VBD was)
          (VP (VBN detected)
            (PP (IN by)
              (NP
                (NP (NN horseradish) (JJ peroxidase-conjugated) (JJ anti-rabbit) (NN IgG) (NN antibody))
                (VP (VBN diluted)
                  (PP (IN at)
                    (NP
                      (NP (NN 1/4000))
                      (PP (IN with)
                        (NP
                          (NP (JJ Tris-buffered) (NN saline))
                          (PP (IN with)
                            (NP
                              (ADJP (CD 0.1) (NN %))
                              (NNP Tween) (CD 20)))
                          (PP (IN with)
                            (NP
                              (ADJP (CD 5) (NN %))
                              (NN BSA))))))))))))
        (, ,)
        (CC and)
        (VP (VBD was)
          (VP (VBN revealed)
            (S
              (VP (VBG using)
                (NP (DT the) (NN chemiluminescence) (NN system))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN Protein) (NNS bands))
        (VP (VBD were)
          (VP (VBN quantified)
            (PP (IN by)
              (NP (NN densitometry)))
            (S
              (VP (VBG using)
                (NP (NN NIH-Image) (NN analysis)))))))
      (, ,)
      (CC and)
      (S
        (NP (NN STAT) (NN phosphorylation))
        (VP (VBD was)
          (VP (VBN compared)
            (PP (IN with)
              (NP
                (NP (DT the) (JJ total) (NN amount))
                (PP (IN of)
                  (NP (NN STAT) (NN protein)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ IFN-γ-stimulated) (NN Hela) (NNS cells))
      (VP (VBD were)
        (VP (VBN used)
          (PP (IN as)
            (NP
              (NP (DT a) (JJ positive) (NN control))
              (PP (IN for)
                (NP (NN STAT1) (NN phosophorylation))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Data))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (DT the) (NN mean) (NN value))
              (VP (VBG ±)
                (NP
                  (NP (JJ standard) (NN error))
                  (PP (IN of)
                    (NP (DT the) (NN mean)
                      (CC or)
                      (NN box) (NNS plots))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ statistical) (NN significance))
        (PP (IN of)
          (NP
            (NP (NNS differences))
            (PP (IN between)
              (NP (CD two) (NNS groups))))))
      (VP (VBD was)
        (VP (VBN determined)
          (PP (IN by)
            (NP
              (NP (DT the) (NN Mann–Whitney) (NN U) (NN test))
              (CC or)
              (NP (DT the) (NN Wilcoxon) (JJ signed) (NN rank) (NN test)))))))
    (. .)))

(
  (S
    (S
      (NP (NN P) (NN <) (CD 0.05))
      (VP (VBD was)
        (VP (VBN considered)
          (ADJP (JJ significant)))))
    (. .)))

(
  (S
    (NP (NNS Results))))

(
  (S
    (S
      (S
        (NP (DT The) (NN CD28) (NN costimulatory) (NN pathway))
        (VP (VBZ is)
          (ADJP (JJ crucial)
            (PP (IN for)
              (NP (JJ effective) (JJ antigen-specific) (NN T-cell) (NN cytokine) (NN production))))))
      (, ,)
      (CC and)
      (S
        (NP (NN IL-10))
        (VP (MD can)
          (ADVP (RB directly))
          (VP (VB suppress)
            (NP (DT this) (NN response))
            (PP (IN by)
              (S
                (VP (VBG inhibiting)
                  (NP
                    (NP (NN CD28) (NN tyrosine) (NN phosphorylation))
                    (CC and)
                    (NP
                      (NP (NN binding))
                      (PP (IN of)
                        (NP (NN phosphatidylinositol) (NN 3-kinase) (CD -LSB-24))))))
                (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (S
        (S
          (VP (TO To)
            (VP (VB evaluate)
              (NP
                (NP (DT the) (NN responsiveness))
                (PP (IN of)
                  (NP (NN RA) (JJ CD4+) (NN T) (NNS cells)))
                (PP (TO to)
                  (NP (NN IL-10)))))))
        (, ,)
        (NP
          (NP (VBN purified) (NN PB) (JJ CD4+) (NN T) (NNS cells))
          (PP
            (PP (IN from)
              (NP
                (NP (CD three) (NNS patients))
                (PP (IN with)
                  (NP (JJ active) (NN RA)))))
            (CC and)
            (PP (IN from)
              (NP (CD three) (JJ healthy) (NNS controls)))))
        (VP (VBD were)
          (VP (VBN stimulated)
            (PP (IN by)
              (NP
                (NP (VBN immobilized) (JJ anti-CD3) (NN antibody))
                (CC and)
                (NP (JJ anti-CD28) (NN antibody))))
            (PP (IN with)
              (CC or)
              (PP (IN without)
                (NP
                  (NP (JJ diluted) (NNS concentrations))
                  (PP (IN of)
                    (NP (NN IL-10))))))
            (PP (IN for)
              (NP (CD 36) (NNS hours))))))
      (, ,)
      (CC and)
      (S
        (NP (NN IFN-γ) (NN production))
        (VP (VBD was)
          (VP (VBN measured)
            (PP (IN by)
              (NP (NN ELISA)))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN As)
        (S
          (VP (VBN shown)
            (PP (IN in)
              (NP (NNP Fig.) (CD 1))))))
      (, ,)
      (NP
        (NP (NN IFN-γ) (NN production))
        (PP (IN by)
          (NP (VBN activated) (JJ normal) (JJ CD4+) (NN T) (NNS cells))))
      (VP (VBD was)
        (ADVP (RB mostly))
        (VP (VBN inhibited)
          (PP (IN at)
            (NP
              (NP (NNS concentrations))
              (ADJP (RB as) (JJ low)
                (PP (IN as)
                  (NP
                    (ADJP (CD 1) (NN ng/ml))
                    (NN IL-10)))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (S
        (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))
        (VP (VBD were)
          (ADJP (JJ able)
            (S
              (VP (TO to)
                (VP (VB produce)
                  (NP
                    (NP (JJ significant) (NNS amounts))
                    (PP (IN of)
                      (NP (NN IFN-γ))))
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN presence))
                      (PP (IN of)
                        (NP
                          (ADJP (CD 1) (NN ng/ml))
                          (NN IL-10)))))))))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (DT the)
            (ADJP
              (ADJP (JJ maximal))
              (CONJP (CC but)
                (RB not))
              (ADJP (JJ complete)))
            (NN inhibition))
          (PP (IN by)
            (NP (NN IL-10))))
        (VP (VBD was)
          (VP (VBN obtained)
            (PP (IN at)
              (NP (CD 10–100) (NN ng/ml)))))))
    (. .)))

(
  (S
    (NP (PRP We))
    (ADVP (RB thus))
    (VP (VBD compared)
      (NP
        (NP (DT the) (NNS levels))
        (PP (IN of)
          (NP
            (NP (NN IFN-γ) (NN production))
            (PP (IN by)
              (NP (JJ CD4+) (NN T) (NNS cells))))))
      (PP (IN after)
        (NP
          (NP
            (NP (NN CD3))
            (CC and)
            (NP (NN CD28)))
          (NN costimulation)))
      (PP (IN in)
        (NP
          (NP (DT the) (NN presence))
          (PP (IN of)
            (NP
              (ADJP (CD 1) (NN ng/ml))
              (NN IL-10)))
          (PP
            (PP (IN in)
              (NP
                (NP (NN RA) (NNS patients))
                (PP (IN with)
                  (NP
                    (NP
                      (NP (JJ active) (NN disease))
                      (PRN (-LRB- -LRB-)
                        (NP
                          (NP (JJ multiple) (JJ inflammatory) (NNS joints))
                          (, ,)
                          (NP (NN CRP) (NN level) (NN ≥) (CD 10) (NN mg/l)))
                        (-RRB- -RRB-)))
                    (CC and)
                    (NP
                      (NP (JJ inactive) (NN disease))
                      (PRN (-LRB- -LRB-)
                        (PP (IN in)
                          (NP (NN remission)))
                        (, ,)
                        (NP (NN CRP) (NN level) (NN <) (CD 10) (NN mg/l) (-RRB- -RRB-) (CD -LSB-26))
                        (-RRB- -RSB-)))))))
            (CC and)
            (PP (IN in)
              (NP (JJ healthy) (NNS controls)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (EX There))
        (VP (VBD were)
          (NP
            (NP (DT no)
              (ADJP (RB statistically) (JJ significant))
              (NNS differences))
            (PP (IN in)
              (NP
                (NP (JJ IFN-γ) (NN production))
                (PP (IN without)
                  (NP (NN IL-10)))
                (PP (IN among)
                  (NP
                    (NP (DT these) (CD three) (NNS groups))
                    (PRN (-LRB- -LRB-)
                      (NP (NNP Fig.) (NN 2a))
                      (-RRB- -RRB-)))))))))
      (, ,)
      (CC but)
      (S
        (NP
          (NP (DT the) (JJ inhibitory) (NN effect))
          (PP (IN of)
            (NP (NN IL-10)))
          (PP (IN on)
            (NP (NN IFN-γ) (NN production))))
        (VP (VBD was)
          (ADVP (RB significantly))
          (VP (VBN limited)
            (PP (IN in)
              (NP (DT the) (JJ active) (NN RA) (NN group)))
            (SBAR (IN as)
              (S
                (VP (VBN compared)
                  (PP (IN with)
                    (NP
                      (NP (DT the) (JJ inactive) (NN RA) (NN group))
                      (CC and)
                      (NP
                        (NP
                          (NP (JJ healthy) (NNS controls))
                          (PRN (-LRB- -LRB-)
                            (NP (NN percentage) (NN decrease))
                            (: :)
                            (NP (JJ active) (NN RA))
                            (, ,)
                            (NP (CD 2.9) (NN ±) (CD 14.4) (NN %))
                            (: ;)
                            (NP (JJ inactive) (NN RA))
                            (, ,)
                            (NP (CD 45.6) (NN ±) (CD 14.4) (NN %))
                            (: ;)
                            (NP (NNS controls))
                            (, ,)
                            (NP (CD 65.8) (NN ±) (CD 7.9) (NN %))
                            (-RRB- -RRB-)))
                        (PRN (-LRB- -LRB-)
                          (NP (NNP Fig.) (NN 2b))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN As)
        (NP (DT a) (NN consequence)))
      (, ,)
      (NP
        (NP (JJ CD4+) (NN T) (NNS cells))
        (PP (IN from)
          (NP (JJ active) (NN RA) (NNS patients))))
      (VP (VBD produced)
        (NP
          (NP (JJR higher) (NNS levels))
          (PP (IN of)
            (NP (NN IFN-γ))))
        (PP (IN in)
          (NP
            (NP (DT the) (NN presence))
            (PP (IN of)
              (NP
                (ADJP (CD 1) (NN ng/ml))
                (NN IL-10)))))
        (SBAR (IN than)
          (SINV (VBD did)
            (NP
              (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP (NNP Fig.) (NN 2a))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (NN addition)))
    (, ,)
    (NP (PRP we))
    (VP (VBD compared)
      (NP
        (NP (NN IL-2) (NN production))
        (PP (IN by)
          (NP (JJ CD4+) (NN T) (NNS cells))))
      (PP (IN after)
        (NP
          (NP (NN CD3))
          (CC and)
          (NP (NN CD28))
          (NP (NN costimulation))))
      (PP
        (PP (IN in)
          (NP
            (NP (DT the) (NN presence))
            (PP (IN of)
              (NP (NN IL-10)))
            (PP (IN in)
              (NP (JJ active) (NN RA) (NNS patients)))))
        (CC and)
        (PP (IN in)
          (NP (JJ healthy) (NNS controls)))))
    (. .)))

(
  (S
    (ADVP (RB Similarly))
    (, ,)
    (NP (NN IL-2) (NN production))
    (VP (VBD was) (RB not)
      (VP (VBN affected)
        (PP (IN by)
          (NP
            (ADJP (CD 1) (NN ng/ml))
            (NN IL-10)))
        (PP (IN in)
          (NP
            (NP (NN RA) (NNS patients))
            (PRN (-LRB- -LRB-)
              (NP (NN percentage) (NN decrease))
              (, ,)
              (NP
                (QP (CD -2.1) (CD ±) (CD 13.8))
                (NN %))
              (-RRB- -RRB-)))))
      (, ,)
      (SBAR (IN while)
        (S
          (NP (PRP it))
          (VP (VBD was)
            (ADVP (RB significantly))
            (VP (VBN reduced)
              (PP (IN in)
                (NP
                  (NP (JJ healthy) (NNS controls))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 61.1) (NN ±) (CD 13.7) (NN %))
                    (: ;)
                    (NP (NN P) (NN <) (CD 0.05))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (VBN Taken)
          (ADVP (RB together))))
      (, ,)
      (NP (DT these) (NNS results))
      (VP (VBP indicate)
        (SBAR (IN that)
          (S
            (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))
            (VP (VBP become)
              (ADJP (RBR less) (JJ susceptible)
                (PP (TO to)
                  (NP
                    (NP (DT the) (JJ immunoregulatory) (NN effect))
                    (PP (IN of)
                      (NP (NN IL-10))))))
              (PP (IN during)
                (NP (DT the) (JJ active) (NN phase))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ functional) (NN receptor) (NN complex))
        (PP (IN of)
          (NP (NN IL-10))))
      (VP (VBZ consists)
        (PP (IN of)
          (NP
            (NP (CD two) (NNS subunits))
            (, ,)
            (NP
              (NP (DT the) (JJ primary) (JJ ligand-binding) (NN component) (NN IL-10R1))
              (CC and)
              (NP (DT the) (JJ accessory) (NN component) (NN type) (CD 2) (NN IL-10R) (CD -LSB-1) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-10R1) (NN expression))
      (VP (VBZ plays)
        (NP (DT a) (JJ critical) (NN role))
        (PP (IN in)
          (NP
            (NP (JJ cellular) (NNS responses))
            (PP (TO to)
              (NP (NN IL-10) (CD -LSB-29))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (VP (TO To)
        (VP (VB examine)
          (SBAR (IN whether)
            (S
              (NP
                (NP (DT the) (NN resistance))
                (PP (TO to)
                  (NP (NN IL-10) (NN inhibition)))
                (PP (IN in)
                  (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))))
              (VP (VBD was)
                (ADJP (JJ due)
                  (PP (TO to)
                    (NP (JJ limited) (NN receptor) (NN expression))))))))))
    (, ,)
    (NP
      (NP (DT the) (NN cell) (NN surface) (NN expression))
      (PP (IN of)
        (NP (NN IL-10R1)))
      (PP (IN on)
        (NP
          (NP (NN PB) (JJ CD4+) (NN T) (NNS cells))
          (PP
            (PP (IN from)
              (NP (JJ active) (NN RA) (NNS patients)))
            (CC and)
            (PP (IN from)
              (NP (JJ healthy) (NNS controls)))))))
    (VP (VBD was)
      (VP (VBN determined)
        (PP (IN by)
          (NP (NN flow) (JJ cytometric) (NN analysis)))))
    (. .)))

(
  (S
    (SBAR (IN As)
      (S
        (VP (VBN shown)
          (PP (IN in)
            (NP (NNP Fig.) (CD 3a,3b))))))
    (, ,)
    (NP
      (NP (DT the) (NN intensity))
      (PP (IN of)
        (NP (NN IL-10R1) (NN expression)))
      (PP (IN on)
        (NP (JJ CD4+) (NN T) (NNS cells))))
    (VP (VBD was)
      (ADVP (RB significantly))
      (VP (VBN increased)
        (PP (IN in)
          (NP (NN RA) (NNS patients)))
        (PP (VBN compared)
          (PP (IN with)
            (PP (IN in)
              (NP (JJ healthy) (NNS controls)))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBP suggest)
        (SBAR (IN that)
          (S
            (NP
              (NP (DT the) (JJ intracellular) (NN signal) (NN transduction) (NN pathway))
              (PP (IN of)
                (NP (NN IL-10))))
            (VP (MD may)
              (VP (VB be)
                (VP (VBN impaired)
                  (PP (IN in)
                    (NP
                      (NP (JJ CD4+) (NN T) (NNS cells))
                      (PP (IN of)
                        (NP (JJ active) (NN RA))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (NN interaction))
      (PP (IN of)
        (NP (NN IL-10R)))
      (PP (IN with)
        (NP (NN IL-10))))
    (VP (VBZ induces)
      (NP
        (NP (NN tyrosine) (NN phosphorylation))
        (CC and)
        (NP
          (NP (NN activation))
          (PP (IN of)
            (NP (DT the) (JJ latent) (NN transcription) (NNS factors)
              (NP
                (NP (NN STAT1))
                (CC and)
                (NP (NN STAT3) (CD -LSB-3))))))))
    (-RRB- -RSB-) (. .)))

(
  (S
    (S
      (NP (JJ Macrophage-specific) (JJ STAT3-deficient) (NNS mice))
      (VP (VBD demonstrated)
        (SBAR (IN that)
          (S
            (NP (NN STAT3))
            (VP (VBZ plays)
              (NP (DT a) (JJ dominant) (NN role))
              (PP (IN in)
                (NP
                  (NP
                    (NP (JJ IL-10-mediated) (JJ anti-inflammatory) (NNS responses))
                    (CD -LSB-5) (-RRB- -RSB-))
                  (, ,)
                  (SBAR
                    (WHNP (WDT which))
                    (S
                      (VP (VBZ has)
                        (ADVP (RB recently))
                        (VP (VBN been)
                          (VP (VBN confirmed)
                            (PP (IN in)
                              (NP (JJ human) (NNS macrophages)))
                            (PP (IN by)
                              (NP
                                (NP (NNS studies))
                                (PP (IN of)
                                  (NP (JJ dominant-negative) (NN STAT3) (NN overexpression) (CD -LSB-30) (-RRB- -RSB-)))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN induction))
        (PP (IN of)
          (NP
            (NP (NN STAT1))
            (CC and)
            (NP (NN STAT3))
            (NP (NN phosphorylation))))
        (PP (IN by)
          (NP (NN IL-10)))
        (PP (IN in)
          (NP
            (NP (NN PB) (JJ CD4+) (NN T) (NNS cells))
            (PP
              (PP (IN from)
                (NP (JJ active) (NN RA) (NNS patients)))
              (CC and)
              (PP (IN from)
                (NP (JJ healthy) (NNS controls)))))))
      (VP (VBD was)
        (VP (VBN examined)
          (S
            (VP (VBG using)
              (NP (NN western) (NN blotting)))))))
    (. .)))

(
  (S
    (S
      (NP (NN STAT3) (NN phosphorylation))
      (VP (VBD was)
        (ADVP (RB dose-dependently))
        (VP (VBN induced)
          (PP (IN after)
            (NP (NN IL-10) (NN activation)))
          (PP (IN for)
            (NP
              (NP (CD 20) (NN min))
              (PP (IN in)
                (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells)))))
          (PRN (-LRB- -LRB-)
            (NP (NNP Fig.) (CD 4a,4b))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (S
        (NP (NN STAT3))
        (VP (VBD was)
          (VP (VBN phosphorylated)
            (PP (IN in)
              (NP
                (NP
                  (ADJP (RB freshly) (VBN isolated))
                  (NN PB) (JJ CD4+) (NNS cells))
                (PP (IN from)
                  (NP (NN RA) (NNS patients))))))))
      (CC and)
      (S
        (NP (DT this) (NN STAT3) (NN phosphorylation))
        (VP (VBD was)
          (ADJP (JJ detectable)
            (PP (IN for)
              (NP
                (QP (RB up) (TO to) (CD 6))
                (NNS hours)))))))
    (. .)))

(
  (S
    (S
      (NP (NN STAT3) (NN phosphorylation))
      (VP (VBD was)
        (VP (VBN augmented)
          (SBAR
            (WHADVP (RB only) (WRB when))
            (S
              (VP (VBN activated)
                (PP (IN by)
                  (NP
                    (ADJP
                      (QP (RB as) (JJ much) (IN as) (CD 10))
                      (NN ng/ml))
                    (NN IL-10)))))))))
    (. .)))

(
  (S
    (S
      (NP (CC Both)
        (NP (JJ sustained) (NN STAT3) (NN phosphorylation))
        (CC and)
        (NP (JJ defective) (JJ IL-10-induced) (NN STAT3) (NN phosphorylation)))
      (VP (VBD were)
        (VP (VBN found)
          (PP (IN in)
            (NP
              (NP (NN RA) (JJ ST) (JJ CD4+) (NN T) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP (NNP Fig.) (NN 4c))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (PP (IN On)
        (NP (DT the) (JJ other) (NN hand)))
      (, ,)
      (NP (JJ IL-10-induced) (NN STAT1) (NN phosphorylation))
      (VP (VBD was) (RB not)
        (VP (VBN detected)
          (PP (IN in)
            (NP (CC either)
              (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))
              (CC or)
              (NP
                (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Fig.) (NN 4a))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBP indicate)
        (SBAR (IN that)
          (S
            (S
              (NP (NN STAT3))
              (VP (VBZ is)
                (NP
                  (NP (DT the) (JJ major) (JJ IL-10-activated) (NN STAT))
                  (PP (IN in)
                    (NP (JJ CD4+) (NN T) (NNS cells))))))
            (, ,)
            (CC and)
            (S
              (NP (JJ IL-10-induced) (NN STAT3) (NN activation))
              (VP (MD may)
                (VP (VB be)
                  (VP (VBN diminished)
                    (PP (IN in)
                      (NP (JJ active) (NN RA)))
                    (, ,)
                    (PP (IN in)
                      (NP
                        (NP (NN association))
                        (PP (IN with)
                          (NP (JJ sustained) (NN STAT3) (NN phosphorylation)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN STAT3))
      (VP (VBZ is)
        (VP (VBN activated)
          (PP (IN by)
            (NP
              (NP
                (NP (JJ many) (NNS cytokines))
                (CC and)
                (NP (NN growth) (NNS factors)))
              (PP (JJ such) (IN as)
                (NP
                  (NP (DT the) (NN IL-6) (NN family))
                  (PP (IN of)
                    (NP
                      (NP
                        (NP (NNS cytokines))
                        (PRN (-LRB- -LRB-)
                          (NP
                            (NP (NN IL-6))
                            (, ,)
                            (NP (NN IL-11))
                            (, ,)
                            (NP (NN leukemia) (JJ inhibitory) (NN factor))
                            (, ,)
                            (CC and)
                            (NP (NN oncostatin) (NN M)))
                          (-RRB- -RRB-)))
                      (, ,)
                      (NP (JJ platelet-derived) (NN growth) (NN factor))
                      (, ,)
                      (CC and)
                      (NP (JJ epidermal) (NN growth) (NN factor))))))))
          (, ,)
          (PP (IN in) (NN addition) (TO to)
            (NP (NN IL-10) (NN -LSB-4) (-RRB- -RSB-))))))
    (, ,)
    (CC but)
    (S
      (NP (JJ previous) (NNS studies))
      (VP (VBP have)
        (VP (VBN demonstrated)
          (SBAR (IN that)
            (S
              (NP (NN IL-6))
              (VP (VBZ is)
                (NP
                  (NP (DT the) (JJ major) (NN factor))
                  (PP (IN in)
                    (NP (NN RA) (JJ synovial) (NN fluid)))
                  (SBAR
                    (WHNP (WDT that))
                    (S
                      (VP (VBZ induces)
                        (NP
                          (NP (JJ constitutive) (NN activation))
                          (PP (IN of)
                            (NP (NN STAT3))))
                        (PP (IN in)
                          (NP
                            (NP (JJ mononuclear) (NNS cells))
                            (NP (CD -LSB-31) (-RRB- -RSB-))))))))))))))
    (. .)))

(
  (S
    (SBAR (IN Since)
      (S
        (NP (NN IL-6))
        (VP (VBZ is)
          (ADVP (RB also))
          (ADJP (JJ abundant)
            (PP (IN in)
              (NP
                (NP (NN sera))
                (PP (IN of)
                  (NP (JJ active) (NN RA) (NNS patients))))))
          (, ,)
          (ADVP (RB frequently))
          (VP (VBN detected)
            (PP (IN at)
              (NP (NN >) (CD 1) (NN ng/ml) (CD -LSB-27) (-RRB- -RSB-)))))))
    (, ,)
    (NP (PRP we))
    (VP (VBD examined)
      (SBAR (IN whether)
        (S
          (NP
            (NP (JJ persistent) (NN exposure))
            (PP (IN of)
              (NP (JJ CD4+) (NN T) (NNS cells)))
            (PP (TO to)
              (NP
                (NP (JJ high) (NNS concentrations))
                (PP (IN of)
                  (NP
                    (NP (NN IL-6))
                    (PP (IN in)
                      (NP (DT the) (NN blood) (NN circulation))))))))
          (VP (VBD was)
            (ADJP (JJ responsible)
              (PP (IN for)
                (NP
                  (NP (PRP$ their) (JJ sustained) (NN STAT3) (NN activation))
                  (CC and)
                  (NP
                    (NP (NN resistance))
                    (PP (TO to)
                      (NP (NN IL-10) (NN inhibition)))
                    (PP (IN in)
                      (NP (JJ active) (NN RA)))))))))))
    (. .)))

(
  (S
    (NP (CC Both)
      (NP (NN STAT1))
      (CC and)
      (NP (NN STAT3))
      (NP (NN phosphorylation)))
    (VP (VBD was)
      (VP (VBN activated)
        (PP (IN by)
          (NP (NN IL-6)))
        (PP (IN in)
          (NP
            (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells))
            (PRN (-LRB- -LRB-)
              (S
                (NP (NNS data))
                (VP (RB not) (VBN shown)))
              (-RRB- -RRB-))))
        (, ,)
        (PP (IN in)
          (NP
            (NP (NN agreement))
            (PP (IN with)
              (NP
                (NP (JJ previous) (NNS observations))
                (CD -LSB-4) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (JJ Normal) (JJ CD4+) (NN T) (NNS cells))
        (VP (VBD were)
          (ADVP (RB thus))
          (VP (VBN incubated)
            (PP (IN for)
              (NP (CD 20) (NN min)))
            (PP (IN with)
              (NP
                (NP (NN culture) (NN medium))
                (VP
                  (VP (VBG containing)
                    (NP
                      (NP
                        (ADJP (CD 30) (NN %))
                        (NN serum))
                      (PP (IN from)
                        (NP (JJ active) (NN RA) (NNS patients)))))
                  (CC and)
                  (VP (VBG neutralizing)
                    (NP
                      (NP (JJ anti-IL-6) (NN antibody))
                      (CC or)
                      (NP (NN control) (NN antibody))))))))))
      (, ,)
      (CC and)
      (S
        (NP (NN STAT) (NN phosphorylation))
        (VP (VBD was)
          (VP (VBN examined)
            (PP (IN by)
              (NP (NN western) (NN blot) (NN analysis)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN RA) (NN serum))
        (VP (VBD was)
          (ADJP (JJ able)
            (S
              (VP (TO to)
                (VP (VB induce)
                  (NP
                    (NP (NN tyrosine) (NN phosphorylation))
                    (PP (IN of)
                      (NP
                        (NP (NN STAT3))
                        (CONJP (CC but)
                          (RB not))
                        (NP (NN STAT1)))))))))))
      (, ,)
      (CC and)
      (S
        (NP (DT this) (NN STAT3) (NN activation))
        (VP (VBD was)
          (ADVP (RB mostly))
          (VP (VBN abolished)
            (PP (IN by)
              (NP
                (NP (NN neutralization))
                (PP (IN of)
                  (NP
                    (NP (NN IL-6) (NN activity))
                    (PRN (-LRB- -LRB-)
                      (NP (NNP Fig.) (NN 5a))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBP indicate)
        (SBAR (IN that)
          (S
            (NP (NN IL-6))
            (VP (VBZ is)
              (NP
                (NP (DT the) (JJ dominant) (NN STAT3-activating) (NN factor))
                (VP (VBN contained)
                  (PP (IN in)
                    (NP
                      (NP (NN sera))
                      (PP (IN of)
                        (NP (JJ active) (NN RA) (NNS patients))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN lack))
        (PP (IN of)
          (NP (NN STAT1) (NN activation)))
        (PP (IN by)
          (NP (NN RA) (NN serum))))
      (VP (VBZ suggests)
        (SBAR
          (SBAR (IN that)
            (S
              (NP
                (NP
                  (ADJP (RB much) (JJR higher))
                  (NNS concentrations))
                (PP (IN of)
                  (NP (NN IL-6))))
              (VP (MD may)
                (VP (VB be)
                  (VP (VBN required)
                    (PP (IN for)
                      (NP (NN STAT1) (NN activation)))))
                (SBAR (IN as)
                  (S
                    (VP (VBN compared)
                      (PP (IN with)
                        (NP (NN STAT3) (NN activation)))))))))
          (, ,)
          (CC or)
          (SBAR (IN that)
            (S
              (NP
                (NP (NNS inhibitors))
                (PP (IN of)
                  (NP (NN STAT1) (NN signaling))))
              (VP (MD may)
                (VP (VB be)
                  (ADJP (JJ present)
                    (PP (IN in)
                      (NP (NN RA) (NN serum)))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (ADVP (RB next))
      (VP (VBD examined)
        (SBAR (IN whether)
          (S
            (NP (NN IL-6))
            (VP (MD could)
              (VP (VB suppress)
                (NP
                  (NP (DT the) (NN effect))
                  (PP (IN of)
                    (NP (NN IL-10)))
                  (S
                    (VP (TO to)
                      (VP (VB inhibit)
                        (NP
                          (NP (NN IFN-γ) (NN production))
                          (PP (IN by)
                            (NP (JJ CD4+) (NN T) (NNS cells))))))))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (NN preincubation))
        (PP
          (PP (IN with))
          (CC or)
          (PP (IN without)
            (NP
              (ADJP (CD 10) (NN ng/ml))
              (NN IL-6))))
        (PP (IN for)
          (NP (CD 36) (NNS hours)))))
    (, ,)
    (S
      (S
        (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells))
        (VP (VBD were)
          (VP (VBN stimulated)
            (PP (IN by)
              (NP
                (NP
                  (NP (NN CD3))
                  (CC and)
                  (NP (NN CD28)))
                (NN costimulation)))
            (PP (IN in)
              (NP
                (NP (DT the)
                  (NP (NN presence))
                  (CC or)
                  (NP (NN absence)))
                (PP (IN of)
                  (NP
                    (ADJP (CD 1) (NN ng/ml))
                    (NN IL-10)))
                (PP (IN for)
                  (NP (CD 36) (NNS hours))))))))
      (, ,)
      (CC and)
      (S
        (NP (DT the) (JJ IFN-γ) (NN production))
        (VP (VBD was)
          (VP (VBN measured)
            (PP (IN by)
              (NP (NN ELISA)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN IL-6) (NN pretreatment))
        (PP (IN of)
          (NP (JJ normal) (NNS cells))))
      (VP (VBD reduced)
        (NP
          (NP (JJ IL-10-mediated) (NN inhibition))
          (PP (IN of)
            (NP
              (NP (JJ IFN-γ) (NN production))
              (PRN (-LRB- -LRB-)
                (NP (NNP Fig.) (NN 5b))
                (-RRB- -RRB-)))))
        (, ,)
        (S
          (VP (VBG indicating)
            (SBAR (IN that)
              (S
                (NP
                  (NP (JJ high) (NNS concentrations))
                  (PP (IN of)
                    (NP (NN IL-6))))
                (VP (MD could)
                  (VP (VB modulate)
                    (NP
                      (NP (NN T-cell) (NN responsiveness))
                      (PP (TO to)
                        (NP (NN IL-10))))))))))))
    (. .)))

(
  (S
    (S
      (VP (VBN Taken)
        (ADVP (RB together))))
    (, ,)
    (S
      (NP (DT these) (NNS findings))
      (VP (VBP suggest)
        (SBAR (IN that)
          (S
            (NP
              (NP (JJ persistent) (NN exposure))
              (PP (TO to)
                (NP (NN serum) (NN IL-6))))
            (VP (MD may)
              (VP (VB have)
                (NP (DT a) (NN role))
                (PP (IN in)
                  (NP (CC both)
                    (NP
                      (NP (DT the) (NN induction))
                      (PP (IN of)
                        (NP (NN STAT3) (NN activation))))
                    (CC and)
                    (NP
                      (NP (DT the) (NN resistance))
                      (PP (TO to)
                        (NP
                          (NP (DT the) (JJ inhibitory) (NN effect))
                          (PP (IN of)
                            (NP (NN IL-10)))
                          (PP (IN in)
                            (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-6))
      (VP (VBZ induces)
        (NP
          (NP (CD two) (JJ potent) (NNS inhibitors))
          (PP (IN of)
            (NP
              (NP
                (NP (NNS JAKs))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP
                      (NP (NN SOCS1))
                      (CC and)
                      (NP (NN SOCS3)))
                    (NNS proteins))
                  (-RRB- -RRB-)))
              (SBAR
                (WHNP (WDT that))
                (S
                  (VP
                    (CONJP (RB not) (RB only))
                    (VP (VBP act)
                      (PP (IN as)
                        (NP
                          (NP (NNS mediators))
                          (PP (IN of)
                            (NP (JJ negative) (NN feedback) (NN inhibition))))))
                    (, ,)
                    (CONJP (CC but)
                      (RB also))
                    (VP (VBP play)
                      (NP (DT a) (JJ major) (NN role))
                      (PP (IN in)
                        (NP (NN crosstalk) (NN inhibition))))))))))
        (PP (IN by)
          (S
            (VP (VBG opposing)
              (NP
                (NP (JJ other) (JJ cytokine-signaling) (NNS pathways))
                (CD -LSB-7) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NN SOCS3))
      (VP (VBZ has)
        (ADVP (RB recently))
        (VP (VBN been)
          (VP (VBN shown)
            (S
              (VP (TO to)
                (ADVP (RB specifically))
                (VP (VB inhibit)
                  (NP
                    (NP (NN STAT3) (NN activation))
                    (VP (VBN induced)
                      (PP
                        (PP (IN by)
                          (NP (NN IL-6)))
                        (CC but)
                        (PP (RB not) (IN by)
                          (NP (NN IL-10))))))
                  (, ,)
                  (S
                    (ADVP (RB thereby))
                    (VP (VBG regulating)
                      (NP
                        (NP (DT the) (JJ divergent) (NN action))
                        (PP (IN of)
                          (NP
                            (NP (NN IL-6))
                            (CC and)
                            (NP (NN IL-10))
                            (NP (NN -LSB-8,9))))))
                    (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN On)
        (NP (DT the) (NN contrary)))
      (, ,)
      (NP (NN SOCS1))
      (VP (VBZ is)
        (ADJP (JJ able)
          (S
            (VP (TO to)
              (ADVP (RB partially))
              (VP (VB inhibit)
                (NP
                  (NP
                    (NP (JJ IL-10-mediated) (NN STAT3) (NN activation))
                    (CC and)
                    (NP (JJ cellular) (NNS responses)))
                  (, ,)
                  (CONJP (RB as) (RB well) (IN as))
                  (NP (JJ IFN-γ-mediated) (NN STAT1) (NN activation) (CD -LSB-32)))))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB determine)
            (SBAR (IN whether)
              (S
                (NP (NNS SOCSs))
                (VP (VBD were)
                  (VP (VBN involved)
                    (PP (IN in)
                      (NP
                        (NP (DT the) (JJ defective) (JJ IL-10-induced) (NN STAT3) (NN activation))
                        (PP (IN of)
                          (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))))))))))))
      (, ,)
      (NP
        (NP (DT the) (NNS levels))
        (PP (IN of)
          (NP
            (NP (NN SOCS1))
            (CC and)
            (NP (NN SOCS3))
            (NP (NN mRNA) (NN expression))))
        (PP (IN in)
          (NP
            (NP (NN PB) (JJ CD4+) (NN T) (NNS cells))
            (PP
              (PP (IN from)
                (NP (JJ active) (NN RA) (NNS patients)))
              (CC and)
              (PP (IN from)
                (NP (JJ healthy) (NNS controls)))))))
      (VP (VBD were)
        (VP (VBN compared)
          (PP (IN by)
            (NP (JJ semiquantitative) (JJ real-time) (NN PCR))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN RA) (JJ CD4+) (NN T) (NNS cells))
      (VP (VBD contained)
        (NP
          (NP
            (NP (JJR higher) (NNS levels))
            (PP (IN of)
              (NP (NN SOCS1))))
          (CC but)
          (NP
            (NP (JJR lower) (NNS levels))
            (PP (IN of)
              (NP (NN SOCS3) (NNS transcripts)))))
        (SBAR (IN than)
          (SINV (VBD did)
            (NP
              (NP (JJ control) (JJ CD4+) (NN T) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP (NNP Fig.) (CD 6a))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Constitutive) (NN expression))
        (PP (IN of)
          (NP (NN SOCS1) (NN mRNA)))
        (PP (IN in)
          (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))))
      (VP (VBD was)
        (ADJP (JJ comparable)
          (PP (IN with)
            (NP
              (NP (DT the) (NN expression))
              (PP (IN in)
                (NP
                  (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells))
                  (VP (VBN stimulated)
                    (PP (IN by)
                      (NP
                        (NP
                          (ADJP (CD 10) (NN ng/ml))
                          (NN IL-6))
                        (PRN (-LRB- -LRB-)
                          (NP (NNP Fig.) (CD 6b))
                          (-RRB- -RRB-))))))))))
        (, ,)
        (S
          (VP (VBG supporting)
            (NP (PRP$ its) (JJ functional) (NN significance))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Defective) (JJ IL-10-induced) (NN STAT3) (NN activation))
      (ADVP (RB therefore))
      (VP (VBZ appears)
        (S
          (VP (TO to)
            (VP (VB be)
              (ADJP (JJ due)
                (PP
                  (ADVP (IN at) (JJS least))
                  (IN in)
                  (NP (NN part)))
                (PP (TO to)
                  (NP
                    (NP (DT an) (NN abundance))
                    (PP (IN of)
                      (NP (NN SOCS1)))
                    (PP (IN in)
                      (NP (NN RA) (JJ CD4+) (NN T) (NNS cells)))))))))))
    (. .)))

(
  (S
    (NP (NN Discussion))))

(
  (S
    (S
      (NP (JJ CD4+) (NN T) (NNS cells))
      (VP (VBP orchestrate)
        (NP (DT the)
          (ADJP (NN Th1-type) (JJ cell-mediated))
          (JJ immune) (NN response))
        (PP (IN in)
          (NP (NN RA) (NN -LSB-22) (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (NP (VBN Activated) (JJ CD4+) (NN T) (NNS cells))
      (VP (VBP stimulate)
        (NP
          (NP (NNS macrophages))
          (, ,)
          (NP (JJ synovial) (NNS fibroblasts))
          (, ,)
          (NP (NN B) (NNS cells))
          (, ,)
          (CC and)
          (NP (NNS osteoclasts)))
        (PP (IN through)
          (NP
            (NP (DT the) (NN expression))
            (PP (IN of)
              (NP
                (NP (NN cell) (NN surface) (NNS molecules))
                (CC and)
                (NP (NN Th1) (NNS cytokines))))))
        (, ,)
        (S
          (ADVP (RB thereby))
          (VP (VBG contributing)
            (PP (TO to)
              (NP (CC both)
                (NP (DT the) (JJ chronic) (NN inflammation))
                (CC and)
                (NP (DT the) (NN joint) (NN destruction))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ CD4+) (NN T) (NNS cells))
      (VP (VBP require)
        (NP
          (NP
            (NP (CD two) (NNS signals))
            (S
              (VP (TO to)
                (VP (VB be)
                  (VP (VBN activated))))))
          (: ;)
          (NP
            (NP (NN antigen) (NN receptor) (NN occupancy))
            (CC and)
            (NP (JJ CD28-mediated) (NN costimulation))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ ST) (NN lesion)))
      (, ,)
      (NP
        (NP
          (NP (DT the) (NN CD28) (NNS ligands))
          (, ,)
          (NP (CC both)
            (NP (NN CD80))
            (CC and)
            (NP (NN CD86))))
        (, ,)
        (CONJP (RB together) (IN with))
        (NP (NN MHC) (NN class) (CD II) (NNS antigens))
        (, ,))
      (VP (VBP are)
        (ADVP (RB substantially))
        (VP (VBN expressed)
          (PP (IN by)
            (NP
              (NP (JJ antigen-presenting) (NNS cells))
              (PP (JJ such) (IN as)
                (NP
                  (NP (NNS macrophages))
                  (CC and)
                  (NP
                    (NP (JJ dendritic) (NNS cells))
                    (CD -LSB-18-20) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN significance))
        (PP (IN of)
          (NP (NN CD28) (NN engagement)))
        (PP (IN in)
          (NP (DT the) (JJ T-cell-mediated) (NN disease) (NN process))))
      (VP (VBZ has)
        (ADVP (RB recently))
        (VP (VBN been)
          (VP (VBN proven)
            (PP (IN by)
              (NP
                (NP (DT the) (JJ clinical) (NN efficacy))
                (PP (IN of)
                  (NP
                    (NP (PRP$ its) (NN blocker) (JJ cytotoxic) (JJ T-cell-associated) (NN antigen))
                    (NP (CD 4) (-LRB- -LRB-) (CD CD152) (-RRB- -RRB-) (NN -IgG))))
                (PP (IN in)
                  (NP (NN RA) (NNS patients) (CD -LSB-23) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-10))
      (VP (VBZ plays)
        (NP (DT a) (JJ predominant) (NN role))
        (PP (IN in)
          (S
            (VP (VBG limiting)
              (NP
                (ADJP
                  (ADJP (JJ immune))
                  (CC and)
                  (ADJP (JJ inflammatory)))
                (NNS responses))
              (PP (IN by)
                (S
                  (VP (VBG regulating)
                    (NP
                      (NP (DT the) (NN function))
                      (PP (IN of)
                        (NP (CC both)
                          (NP (NNS macrophages))
                          (CC and)
                          (NP
                            (NP (NN Th1) (NNS cells))
                            (PRN (NN -LSB-1) (-RRB- -RSB-))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-10))
      (VP
        (VP (VBZ inhibits)
          (NP
            (NP
              (NP (DT the) (NN tyrosine) (NN phosphorylation))
              (PP (IN of)
                (NP (DT the) (NN CD28) (NN molecule))))
            (CC and)
            (NP
              (NP
                (NP (DT the) (JJ subsequent) (NN phosphatidylinositol) (NN 3-kinase))
                (NN binding))
              (PP (IN in)
                (NP (NN T) (NNS cells))))))
        (, ,)
        (CC and)
        (ADVP (RB thereby))
        (ADVP (RB directly))
        (VP (VBZ acts)
          (PP (IN on)
            (NP (NN T) (NNS cells) (CD -LSB-24) (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT the) (JJ present) (NN study)))
    (, ,)
    (NP (PRP we))
    (VP (VBD found)
      (SBAR (IN that)
        (S
          (NP
            (NP (NN PB) (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP
                (NP (NNS patients))
                (PP (IN with)
                  (NP (JJ active) (NN RA)))))
            (, ,)
            (PP (IN in)
              (NP
                (NP (DT the) (NN presence))
                (PP (IN of)
                  (NP (NN IL-10)))))
            (, ,))
          (VP (VBP are)
            (ADJP (JJ able)
              (S
                (VP (TO to)
                  (VP (VB produce)
                    (NP
                      (NP (JJR higher) (NNS levels))
                      (PP (IN of)
                        (NP (NN IFN-γ))))
                    (PP (IN after)
                      (NP
                        (NP
                          (NP
                            (NP (NN CD3))
                            (CC and)
                            (NP (NN CD28)))
                          (NN costimulation))
                        (PP (IN than)
                          (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells)))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN Despite)
        (NP
          (NP (JJ high-level) (NN IL-10R1) (NN expression))
          (CC and)
          (NP (JJ constitutive) (NN STAT3) (NN activation))))
      (, ,)
      (NP
        (NP (JJ IL-10-induced) (NN tyrosine) (NN phosphorylation))
        (PP (IN of)
          (NP (NN STAT3))))
      (VP (VBZ is)
        (VP (VBN suppressed)
          (PP (IN in)
            (NP (NN RA) (JJ CD4+) (NN T) (NNS cells)))
          (, ,)
          (PP (IN in) (NN contrast) (TO to)
            (NP
              (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells))
              (, ,)
              (SBAR
                (WHADVP (WRB where))
                (S
                  (NP (NN STAT3) (NN phosphorylation))
                  (VP (VBZ is)
                    (ADJP (RB dose-dependently) (JJ inducible)
                      (PP (IN by)
                        (NP (NN IL-10))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (NN Serum) (NN IL-6))
          (PP (IN from)
            (NP (NN RA) (NNS patients))))
        (VP (VBZ induces)
          (NP
            (NP
              (NP
                (NP (NN STAT3))
                (CONJP (CC but)
                  (RB not))
                (NP (NN STAT1)))
              (NN phosphorylation))
            (PP (IN in)
              (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells))))))
      (, ,)
      (CC and)
      (S
        (NP (JJ exogenous) (NN IL-6))
        (VP (VBZ induces)
          (NP
            (NP (DT the) (NN resistance))
            (PP (TO to)
              (NP
                (NP
                  (NP (NN IL-10))
                  (NN inhibition))
                (PP (IN of)
                  (NP (NN IFN-γ) (NN production)))))))))
    (. .)))

(
  (S
    (S
      (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))
      (VP
        (VP (VBP contain)
          (NP
            (NP (JJR higher) (NNS levels))
            (PP (IN of)
              (NP (NN SOCS1)))))
        (CC but)
        (VP (VBP contain)
          (NP
            (NP (JJR lower) (NNS levels))
            (PP (IN of)
              (NP (NN SOCS3) (NNS transcripts)))
            (PP (IN in)
              (NP
                (NP (NN comparison))
                (PP (IN with)
                  (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS findings))
      (VP
        (VP (VBP indicate)
          (SBAR (IN that)
            (S
              (NP (JJ CD4+) (NN T) (NNS cells))
              (VP (VBP become)
                (ADJP (JJ resistant)
                  (PP (TO to)
                    (NP
                      (NP (DT the) (JJ inhibitory) (NN effect))
                      (PP (IN of)
                        (NP (NN IL-10))))))
                (PP (IN before)
                  (NP
                    (NP (NN migration))
                    (PP (IN into)
                      (NP (DT the) (JJ inflamed) (JJ ST)))))))))
        (, ,)
        (CC and)
        (VP (VBP suggest)
          (SBAR (IN that)
            (S
              (NP (DT this) (NN resistance))
              (VP (MD may)
                (VP (VB be)
                  (ADJP (JJ attributable)
                    (PP (TO to)
                      (NP (JJ impaired) (JJ IL-10-dependent) (NN STAT3) (NN activation))))
                  (, ,)
                  (PP (IN in)
                    (NP
                      (NP (NN association))
                      (PP (IN with)
                        (NP
                          (NP (JJ sustained) (NN STAT3) (NN phosphorylation))
                          (CC and)
                          (NP (NN SOCS1) (NN induction)))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ IL-10-mediated) (NN inhibition))
        (PP (IN of)
          (NP (JJ CD4+) (NN T-cell) (NN cytokine) (NN production))))
      (VP (VBZ is)
        (ADVP (RB principally))
        (ADJP (JJ dependent)
          (PP (IN on)
            (NP
              (NP (PRP$ its) (NN inhibition))
              (PP (IN of)
                (NP (NN macrophage) (JJ antigen-presenting) (NN cell) (NN function) (CD -LSB-1)))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (ADVP (RB However))
    (, ,)
    (NP (DT this) (JJ indirect) (JJ inhibitory) (NN effect))
    (VP (VBZ is)
      (VP (VBN thought)
        (S
          (VP (TO to)
            (VP (VB be)
              (VP (VBN restricted)
                (PP (IN at)
                  (NP
                    (NP (DT the) (NN site))
                    (PP (IN of)
                      (NP (NN T-cell) (NN activation)))
                    (PP (IN in)
                      (NP (NN RA)))))))))
        (, ,)
        (SBAR (IN because)
          (S
            (NP
              (NP (NNS macrophages))
              (PP (IN in)
                (NP (DT the) (JJ ST))))
            (VP (VBP express)
              (NP
                (NP (JJ high) (NNS levels))
                (PP (IN of)
                  (NP
                    (NP (NNS cytokines))
                    (, ,)
                    (NP
                      (NP
                        (NP (NN CD80))
                        (CC and)
                        (NP (NN CD86)))
                      (NNS molecules))
                    (, ,)
                    (CC and)
                    (NP
                      (NP (NN MHC) (NN class) (CD II))
                      (NNS antigens))
                    (NP (CD -LSB-10,18-20))))))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (ADVP (RBR More) (RB recently))
      (, ,)
      (NP (NN IL-10))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN shown)
            (S
              (VP (TO to)
                (VP (VB induce)
                  (NP (DT the) (JJ antigen-specific) (NN T-cell) (NN unresponsiveness))
                  (PP (IN by)
                    (S
                      (VP (VBG inhibiting)
                        (NP (NN CD28) (NN tyrosine) (NN phosphorylation) (CD -LSB-33)))))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP (DT This) (JJ direct) (NN effect))
      (VP
        (ADVP (RB also))
        (MD may)
        (VP (VB be)
          (VP (VBN limited)
            (PP (IN in)
              (NP (JJ active) (NN RA) (NNS patients)))
            (, ,)
            (SBAR (IN because)
              (S
                (NP (PRP$ their) (NN PB) (JJ CD4+) (NN T) (NNS cells))
                (VP (VBD showed)
                  (NP
                    (NP
                      (NP (DT a) (JJ defective) (NN IL-10))
                      (NN inhibition))
                    (PP (IN of)
                      (NP
                        (NP (JJ CD28-costimulated) (NN production))
                        (PP (IN of)
                          (NP (CC both)
                            (NP (NN IFN-γ))
                            (CC and)
                            (NP (NN IL-2))))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (JJ Numerous) (NNS cytokines))
          (, ,)
          (ADJP (CC both)
            (ADJP (JJ proinflammatory))
            (CC and)
            (ADJP (JJ anti-inflammatory)))
          (, ,))
        (VP (VBP have)
          (VP (VBN been)
            (VP (VBN detected)
              (PP (IN in)
                (NP
                  (NP (DT the) (JJ ST))
                  (PP (IN of)
                    (NP (NN RA)))))))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (DT the) (NN balance))
          (PP (IN between)
            (NP (DT these) (JJ opposing) (NN cytokine) (NNS activities))))
        (VP (VBZ regulates)
          (NP (NN disease) (NN severity) (CD -LSB-10) (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Endogenous) (NN IL-10))
        (, ,)
        (VP (VBN produced)
          (ADVP (RB mainly))
          (PP (IN by)
            (NP
              (NP (NNS macrophages))
              (CC and)
              (NP (NN T) (NNS cells)))))
        (, ,))
      (VP (VBZ inhibits)
        (NP (JJ proinflammatory) (NN cytokine) (NN production))
        (PP (IN by)
          (NP (JJ ST) (NNS cells) (CD -LSB-12) (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP (DT this) (JJ regulatory) (NN activity))
      (VP (VBZ seems)
        (S
          (VP (TO to)
            (VP (VB be)
              (VP (VBN restricted)
                (PP (IN during)
                  (NP (JJ chronic) (NN inflammation)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN activation))
        (PP (IN of)
          (NP (DT both)
            (NP
              (NP (DT the) (JJ extracellular) (JJ stimulus-regulated) (NN kinase))
              (CC and)
              (NP (NN p38) (NN kinase)))
            (NNS pathways)))
        (, ,)
        (VP (VBN induced)
          (PP (IN by)
            (NP
              (NP (NN TNF-α))
              (CC and)
              (NP (NN IL-1)))))
        (, ,))
      (VP (VBZ inhibits)
        (NP
          (NP (DT the) (NN Jak1–STAT3) (NN signaling) (NN pathway))
          (VP (VBN shared)
            (PP (IN by)
              (NP
                (NP (NN IL-10))
                (CC and)
                (NP (NN IL-6))))))
        (PP (IN in)
          (NP (JJ adhered) (NNS macrophages) (CD -LSB-13) (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (ADVP (RBR More) (RB importantly))
      (, ,)
      (NP (JJ IL-10-mediated) (NN STAT3) (NN activation))
      (VP (VBZ is)
        (ADJP (RB mostly) (JJ undetectable)
          (PP (IN in)
            (NP (NN RA) (JJ synovial) (NNS macrophages))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (JJ impaired) (NN IL-10) (NN signaling))
      (VP (VBZ is)
        (ADVP (RB probably))
        (VP (VBN induced)
          (PP (IN by)
            (NP
              (NP (JJ chronic) (NN exposure))
              (PP (TO to)
                (NP (JJ immune) (NNS complexes)))))
          (ADVP (FW in) (FW vivo)))
        (, ,)
        (SBAR (IN because)
          (S
            (NP (CC both)
              (NP (NN cell) (NN surface) (NN IL-10R1) (NN expression))
              (CC and)
              (NP (JJ IL-10-induced) (NN Jak1) (NN activation)))
            (VP (VBP are)
              (VP (VBN suppressed)
                (PP (IN in)
                  (NP (JJ IFN-γ-primed) (NNS macrophages)))
                (PP (IN by)
                  (NP
                    (NP (DT a)
                      (ADJP (NN protein) (NN kinase) (JJ C-dependent))
                      (NN pathway))
                    (PP (VBG following)
                      (NP
                        (NP (NN ligation))
                        (PP (IN of)
                          (NP (DT the) (NN IgG) (NN Fc) (NN gamma) (NN receptor) (CD -LSB-14)))))))))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Furthermore))
      (, ,)
      (NP
        (NP (JJ dendritic) (NNS cells))
        (PP (IN from)
          (NP (NN RA) (JJ synovial) (NNS fluids))))
      (VP (VBP are)
        (ADJP (JJ resistant)
          (PP (TO to)
            (NP
              (NP (DT the) (JJ immunoregulatory) (NN effect))
              (PP (IN of)
                (NP (NN IL-10)))
              (ADJP (JJ due)
                (PP (TO to)
                  (NP
                    (NP (VBN decreased) (NN transport))
                    (PP (IN of)
                      (NP (JJ intracellular) (NN IL-10R1)))
                    (PP (IN in)
                      (NP
                        (NP (DT the) (NN presence))
                        (PP (IN of)
                          (NP
                            (NP (JJ proinflammatory) (NN cytokine) (NNS stimuli))
                            (PP (JJ such) (IN as)
                              (NP
                                (NP (NN TNF-α))
                                (, ,)
                                (NP (NN IL-1))
                                (, ,)
                                (CC and)
                                (NP (NN granulocyte–macrophage) (JJ colony-stimulating) (NN factor) (CD -LSB-15)))))))))))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBP have)
        (VP (VBN demonstrated)
          (SBAR (IN that)
            (S
              (NP
                (NP (DT the) (NN resistance))
                (PP (IN of)
                  (NP (NN RA) (JJ CD4+) (NN T) (NNS cells)))
                (PP (TO to)
                  (NP (NN IL-10))))
              (VP (MD may)
                (VP (VB be)
                  (VP (VBN associated)
                    (PP
                      (PP (IN with)
                        (NP (JJ defective) (JJ IL-10-dependent) (NN STAT3) (NN activation)))
                      (, ,)
                      (CC but)
                      (PP (RB not) (IN with)
                        (NP (NN IL-10R1) (NN expression))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Inhibitory) (NNS effects))
        (PP (IN of)
          (NP (NN IL-10)))
        (PP (IN on)
          (NP (DT these) (JJ inflammatory) (NN cell) (NNS types))))
      (VP (VBP are)
        (ADVP (RB therefore))
        (ADVP (RB differentially))
        (VP (VBN modulated)
          (PP (IN at)
            (NP (DT the) (NN signal) (NN transduction) (NN level)))
          (PP (IN under)
            (NP
              (NP (DT the) (JJ inflammatory) (NN environment))
              (PP (IN in)
                (NP (NN RA))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (NN association))
          (PP (IN with)
            (NP (JJ impaired) (JJ IL-10-mediated) (NN STAT3) (NN activation)))))
      (, ,)
      (NP (NN STAT3))
      (VP (VBD was)
        (VP (VBN found)
          (S
            (VP (TO to)
              (VP (VB be)
                (NP
                  (NP (NN tyrosine))
                  (VP (VBN phosphorylated)
                    (ADVP (RB persistently))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (QP (RB up) (TO to) (CD 6))
                        (NNS hours))
                      (-RRB- -RRB-))
                    (PP (IN in)
                      (NP
                        (NP
                          (ADJP (RB freshly) (VBN isolated))
                          (NN PB)
                          (CC and)
                          (JJ ST) (JJ CD4+) (NN T) (NNS cells))
                        (PP (IN from)
                          (NP (NN RA) (NNS patients)))))))))))))
    (. .)))

(
  (S
    (NP (NN STAT3))
    (VP (VBZ is)
      (VP (VBN activated)
        (PP (IN by)
          (NP
            (NP (DT a) (NN variety))
            (PP (IN of)
              (NP (NNS cytokines)))))
        (, ,)
        (ADVP (RB notably))
        (NP
          (NP (DT the) (NN IL-6) (NN family))
          (PP (IN of)
            (NP
              (NP (NNS cytokines))
              (PRN (-LRB- -LRB-)
                (PP (FW e.g.))))))))))

(
  (S
    (NP
      (NP
        (NP
          (NP (NN IL-6))
          (, ,)
          (NP (NN IL-11))
          (, ,)
          (NP (NN leukemia) (JJ inhibitory) (NN factor))
          (, ,)
          (CC and)
          (NP (NN oncostatin) (NN M))
          (-RRB- -RRB-)
          (CC and)
          (NP (NN growth) (NNS factors)))
        (PRN (, ,)
          (PP (IN in) (NN addition) (TO to)
            (NP (NN IL-10) (NN -LSB-4)))
          (-RRB- -RSB-)))
      (. .))))

(
  (S
    (PP (IN Of)
      (NP (DT these) (NNS cytokines)))
    (, ,)
    (NP (NN IL-6))
    (VP (VBZ plays)
      (NP (DT a) (JJ predominant) (NN role))
      (PP (IN in)
        (S
          (VP (VBG eliciting)
            (NP (DT a) (JJ systemic) (NN reaction))
            (PP (JJ such) (IN as)
              (NP
                (NP (DT the) (JJ acute) (NN phase) (NN response))
                (PP (IN in)
                  (NP (JJ active) (NN RA))))))))
      (, ,)
      (PP (JJ due)
        (ADVP (RB mainly))
        (TO to)
        (NP
          (NP (PRP$ its) (NN abundance))
          (PP (IN in)
            (NP (DT the) (NN blood) (NN circulation) (CD -LSB-27) (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (S
        (S
          (ADJP (JJ Consistent)
            (PP (IN with)
              (NP (DT this) (NN notion)))))
        (, ,)
        (NP (NN IL-6))
        (VP (VBD was)
          (NP
            (NP (DT the) (JJ major) (NN STAT3-activating) (NN factor))
            (VP (VBN contained)
              (PP (IN in)
                (NP
                  (NP (DT the) (NN serum))
                  (PP (IN of)
                    (NP (JJ active) (NN RA) (NNS patients)))))))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (DT the) (NN responsiveness))
          (PP (TO to)
            (NP (NN IL-10))))
        (VP (VBD was)
          (VP (VBN suppressed)
            (PP (IN in)
              (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells)))
            (PP (IN after)
              (NP
                (NP (CD 36) (NNS hours))
                (PP (IN of)
                  (NP
                    (NP (NN incubation))
                    (PP (IN with)
                      (NP (NN IL-6)))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBP suggest)
        (SBAR (IN that)
          (S
            (NP (CC both)
              (NP (DT the) (JJ sustained) (NN STAT3) (NN activation))
              (CC and)
              (NP
                (NP (DT the) (NN resistance))
                (PP (TO to)
                  (NP (NN IL-10) (NN inhibition)))
                (VP (VBN found)
                  (PP (IN in)
                    (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))))))
            (VP (MD may)
              (VP (VB be)
                (VP (VBN induced)
                  (PP (IN after)
                    (NP (JJ chronic) (NN exposure)))
                  (ADVP (FW in) (FW vivo))
                  (PP (TO to)
                    (NP
                      (NP (JJ high) (NNS concentrations))
                      (PP (IN of)
                        (NP (NN serum) (NN IL-6))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP (PRP it))
      (VP (VBZ is)
        (ADVP (RB also))
        (ADJP (JJ possible))
        (SBAR (IN that)
          (S
            (NP (NN STAT3) (NN activity))
            (VP (MD could)
              (VP (VB be)
                (ADVP (RB constitutively))
                (VP (VBN induced)
                  (PP (IN in)
                    (NP (JJ CD4+) (NN T) (NNS cells)))
                  (PP (IN by)
                    (NP (PRP$ their) (JJ own) (NN IL-10) (NN secretion)))
                  (, ,)
                  (S
                    (VP (VBG leading)
                      (PP (TO to)
                        (NP
                          (NP (DT the) (NN loss))
                          (PP (IN of)
                            (NP
                              (NP (NN sensitivity))
                              (PP (TO to)
                                (NP (JJ exogenous) (NN IL-10))))))))))
                (, ,)
                (SBAR (IN because)
                  (S
                    (NP
                      (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))
                      (PP (IN in)
                        (NP (DT the) (JJ ST))))
                    (VP (VBP are)
                      (ADJP (JJ capable)
                        (PP (IN of)
                          (S
                            (VP (VBG producing)
                              (NP
                                (NP (JJ significant) (NNS levels))
                                (PP (IN of)
                                  (NP (NN IL-10) (CD -LSB-34) (-RRB- -RSB-)))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ CD4+) (NN T) (NNS cells))
        (VP (VBN isolated)
          (PP (IN from)
            (NP
              (NP (DT the) (JJ ST))
              (PP (IN of)
                (NP (NN RA)))))))
      (ADVP (RB also))
      (VP (VBD showed)
        (NP
          (NP (DT a) (NN defect))
          (PP (IN in)
            (NP (DT the) (JJ IL-10-induced) (NN STAT3) (NN signaling) (NN pathway))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBZ is)
        (ADJP (RBS most) (JJ probable)
          (SBAR (IN that)
            (S
              (NP
                (NP (DT the) (NN resistance))
                (PP (IN of)
                  (NP (JJ CD4+) (NN T) (NNS cells)))
                (PP (TO to)
                  (NP (NN IL-10))))
              (VP (MD can)
                (VP (VB be)
                  (ADVP (RB even))
                  (VP (VBN augmented)
                    (PP (IN after)
                      (NP
                        (NP (NN migration))
                        (PP (IN into)
                          (NP (DT the) (JJ inflamed) (JJ ST)))))))))))
        (, ,)
        (SBAR (IN because)
          (S
            (NP (NN IL-6))
            (VP (VBZ is)
              (ADVP (RB highly))
              (VP (VBN concentrated)
                (PP (VBN compared)
                  (PP (IN with)
                    (NP (DT the) (NN blood) (NN level) (CD -LSB-27) (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (NN addition)))
    (, ,)
    (NP
      (NP (DT the) (NN involvement))
      (PP (IN of)
        (NP (JJ other) (JJ essential) (JJ proinflammatory) (NNS cytokines)))
      (PP (IN in)
        (NP (DT this) (NN process))))
    (VP (VBD was)
      (VP (VBN suggested)
        (PP (IN by)
          (NP
            (NP (PRP$ our) (JJ preliminary) (NNS experiments))
            (VP (VBG demonstrating)
              (SBAR (IN that)
                (S
                  (NP
                    (NP (JJ IL-10-mediated) (JJ IFN-γ) (NN inhibition))
                    (PP (IN in)
                      (NP (JJ CD4+) (NN T) (NNS cells))))
                  (VP (VBD was)
                    (VP (VBN reduced)
                      (PP (IN by)
                        (NP
                          (NP (NN pretreatment))
                          (PP (IN with)
                            (NP
                              (NP (NN IL-1β))
                              (CC and)
                              (NP (NN TNF-α)))))))
                    (, ,)
                    (SBAR (IN although)
                      (FRAG
                        (ADVP (JJR less) (RB effectively))
                        (SBAR (IN than)
                          (S
                            (PP (IN by)
                              (NP (NN IL-6)))
                            (PRN (-LRB- -LRB-)
                              (NP
                                (NP (NN data))
                                (VP
                                  (ADVP (RB not))
                                  (VBN shown)))
                              (-RRB- -RRB-))))))))))))))
    (. .)))

(
  (S
    (ADVP (RB Furthermore))
    (, ,)
    (NP
      (NP
        (NP (NN IFN-γ))
        (CC and)
        (NP (NN IL-10)))
      (VP (VBN produced)
        (PP (IN by)
          (NP
            (NP (JJ CD4+) (NN T) (NNS cells))
            (NP (PRP themselves))))))
    (VP (MD could)
      (VP (VB be)
        (ADJP (JJ responsible)
          (PP (IN for)
            (NP
              (NP (JJ impaired) (NN IL-10) (NN signaling))
              (PP (IN in)
                (NP (DT the) (JJ ST))))))
        (, ,)
        (SBAR (IN because)
          (S
            (NP (NN T-cell) (NNS infiltrates))
            (VP (VBP produce)
              (NP (DT both) (NNS cytokines)
                (NP (CD -LSB-34,35))))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT an) (JJ autocrine) (NN fashion)))
      (, ,)
      (S
        (NP (NN IL-10))
        (VP (MD may)
          (ADVP (RB persistently))
          (VP (VB stimulate)
            (NP (NN STAT3) (NN activation)))))
      (CC and)
      (S
        (NP (NN IFN-γ))
        (VP (MD can)
          (VP (VB induce)
            (NP (NN SOCS1) (NN protein))
            (PP (IN as)
              (NP
                (NP (DT a) (NN crosstalk) (NN inhibitor))
                (PP (IN of)
                  (NP (NN IL-10) (NN signaling) (CD -LSB-32)))))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ T-cell-inhibitory) (NN effect))
        (PP (IN of)
          (NP (NN IL-10))))
      (VP (MD may)
        (ADVP (RB therefore))
        (VP (VB be)
          (VP (VBN modulated)
            (ADVP (RB complicatedly))
            (PP (IN upon)
              (NP
                (NP (NN exposure))
                (PP (TO to)
                  (NP
                    (NP (DT an) (JJ inflammatory) (NN environment))
                    (PP (IN in)
                      (NP (NN RA) (NNS joints)))
                    (, ,)
                    (SBAR
                      (WHADVP (WRB where))
                      (S
                        (NP (JJ many) (NNS cytokines))
                        (VP (VBP are)
                          (ADJP (JJ present)
                            (PP (RB substantially)
                              (NP (NN -LSB-10) (-RRB- -RSB-)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN STAT3) (NN activation))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN implicated)
            (PP (IN in)
              (NP
                (NP (DT the) (NN pathogenesis))
                (PP (IN of)
                  (NP (NN RA)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Active) (NN STAT3))
      (VP (VBZ is)
        (ADVP (RB constitutively))
        (VP (VBN expressed)
          (PP (IN in)
            (NP
              (NP (JJ synovial) (NN fluid) (JJ mononuclear) (NNS cells))
              (PP (IN from)
                (NP (NN RA) (NNS patients) (CD -LSB-36) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-6))
      (VP (VBZ is)
        (NP
          (NP (DT the) (JJ major) (JJ STAT3-activating) (NN factor))
          (ADJP (JJ present)
            (PP (IN in)
              (NP
                (NP (JJ synovial) (NN fluid))
                (, ,)
                (SBAR
                  (WHNP (WDT which))
                  (S
                    (VP (VBZ has)
                      (NP (DT a) (JJ crucial) (NN role))
                      (PP (IN in)
                        (NP
                          (NP (DT the) (NN activation))
                          (PP
                            (PP (IN of)
                              (NP
                                (NP (NN monocyte) (NNS functions))
                                (PP (JJ such) (IN as)
                                  (NP
                                    (NP (NN gene) (NN expression))
                                    (PP (IN of)
                                      (NP (DT the) (NN Fc) (NN gamma) (NN receptor)
                                        (NP
                                          (NP (NN type) (CD I))
                                          (CC and)
                                          (NP (NN type) (CD III)))))))))
                            (CC and)
                            (PP (IN of)
                              (NP (NN HLA-DR) (CD -LSB-31) (-RRB- -RSB-)))))))))))))))
    (. .)))

(
  (S
    (ADVP (RBR More) (RB recently))
    (, ,)
    (S
      (S
        (NP
          (NP (JJ high) (NNS levels))
          (PP (IN of)
            (NP (VBN activated)
              (NP (NN STAT3))
              (, ,)
              (VP (VBN thought)
                (S
                  (VP (TO to)
                    (VP (VB be)
                      (VP (VBN induced)
                        (ADVP (RB mainly))
                        (PP (IN by)
                          (NP (NN IL-6))))))))
              (, ,))))
        (VP (VBP have)
          (VP (VBN been)
            (VP (VBN detected)
              (PP (IN in)
                (NP (DT the) (JJ ST)))))))
      (, ,)
      (CC and)
      (S
        (NP (NN STAT3) (NN activation))
        (VP (VBZ has)
          (VP (VBN been)
            (VP (VBN shown)
              (S
                (VP (TO to)
                  (VP (VB be)
                    (VP (VBN involved)
                      (PP (IN in)
                        (NP
                          (NP (JJ synovial) (NN fibroblast) (NN proliferation))
                          (CC and)
                          (NP (NN IL-6) (NN production) (CD -LSB-37) (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT this) (NN regard)))
      (, ,)
      (NP (NN STAT3))
      (VP (VBZ is)
        (ADJP (JJ critical)
          (PP (IN in)
            (NP
              (NP (DT the)
                (NP (NN survival))
                (CC and)
                (NP (NN expansion)))
              (PP (IN of)
                (NP (NN growth) (JJ factor-dependent) (JJ synovial) (NNS fibroblasts)
                  (NP (CD -LSB-38))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (ADVP (RB Furthermore))
    (, ,)
    (NP
      (NP (DT the) (NN significance))
      (PP (IN of)
        (NP (JJ persistent) (NN STAT3) (NN signaling)))
      (PP (IN in)
        (NP (JJ Th1-cell-dominated) (JJ autoimmune) (NN arthritis))))
    (VP (VBZ has)
      (VP (VBN been)
        (VP (VBN suggested)
          (PP (IN by)
            (NP
              (NP (NNS studies))
              (PP (IN of)
                (NP (DT the) (CD gp130F759/F759) (NNS mice)))
              (, ,)
              (SBAR
                (WHPP (IN in)
                  (WHNP (WDT which)))
                (S
                  (NP
                    (NP (DT the) (NN Src) (NN homology) (NN phosphatase-2) (NN binding) (NN site))
                    (PP (IN of)
                      (NP
                        (NP
                          (NP (NN gp130))
                          (PRN (-LRB- -LRB-)
                            (NP
                              (NP (DT the) (JJ transmembrane) (NN glycoprotein) (NN β) (NN subunit))
                              (PP (IN of)
                                (NP (DT the) (NN IL-6) (NN family) (NN cytokine) (NN receptor))))
                            (-RRB- -RRB-)))
                        (, ,)
                        (NP (NN tyrosine) (CD 759))
                        (, ,))))
                  (VP (VBD was)
                    (VP (VBN mutated)
                      (PP (TO to)
                        (NP (NN phenylalanine) (CD -LSB-39) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (CD gp130F759/F759) (NNS mice)))
      (, ,)
      (NP
        (NP (NN T) (NNS cells))
        (, ,)
        (NP
          (ADVP (RB particularly))
          (NP (DT the) (JJ CD4+) (NN T-cell) (NN subset)))
        (, ,))
      (VP (VBP are)
        (ADVP (RB chronically))
        (VP
          (VP (VBN activated))
          (CC and)
          (ADJP (JJ resistant)
            (PP (TO to)
              (NP
                (NP (JJ activation-induced) (NN cell) (NN death))
                (PP (IN through)
                  (NP (JJ gp130-mediated) (NN STAT3) (NN activation)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN longevity))
        (PP (IN of)
          (NP
            (NP (NN cytokine) (NNS signals))
            (VP (VBN transduced)
              (PP (IN by)
                (NP (DT the) (NN JAK–STAT) (NN pathway)))))))
      (VP (VBZ is)
        (VP (VBN regulated)
          (PP (IN by)
            (NP (DT the) (NN SOCS) (NN family) (NNS proteins)
              (NP (CD -LSB-7))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD found)
        (SBAR (IN that)
          (S
            (NP
              (NP (JJ CD4+) (NN T) (NNS cells))
              (PP (IN from)
                (NP
                  (NP (NNS patients))
                  (PP (IN with)
                    (NP (JJ active) (NN RA))))))
            (VP (VBD expressed)
              (NP
                (NP (JJR higher) (NNS levels))
                (PP (IN of)
                  (NP (NN SOCS1))))
              (, ,)
              (CC but)
              (NP
                (NP (JJR lower) (NNS levels))
                (PP (IN of)
                  (NP (NN SOCS3))))
              (, ,)
              (PP (VBN compared)
                (PP (IN with)
                  (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells)))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN SOCS1))
        (VP (VBZ prevents)
          (NP
            (NP (NN activation))
            (PP (IN of)
              (NP (NN JAK))))
          (PP (IN by)
            (S
              (ADVP (RB directly))
              (VP (VBG binding)
                (PP (TO to)
                  (NP (NN JAK))))))))
      (, ,)
      (CC and)
      (S
        (NP (NN SOCS3))
        (VP (VBZ inhibits)
          (NP
            (NP (DT the) (NN action))
            (PP (IN of)
              (NP (NN JAK))))
          (PP (IN by)
            (S
              (VP (VBG binding)
                (PP (TO to)
                  (NP
                    (NP (DT the) (NN Src) (NN homology) (NN phosphatase-2-binding) (NN domain))
                    (PP (IN of)
                      (NP
                        (NP (NNS receptors))
                        (PP (JJ such) (IN as)
                          (NP (NN gp130) (NN -LSB-40) (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN SOCS1))
        (CC and)
        (NP (NN SOCS3)))
      (VP (VBP are)
        (VP (VBN induced)
          (PP (IN by)
            (NP
              (NP (JJ various) (NNS cytokines))
              (, ,)
              (PP (VBG including)
                (NP
                  (NP (NN IL-6))
                  (CC and)
                  (NP (NN IL-10))))
              (, ,)))
          (PP (IN as)
            (NP
              (NP (NNS mediators))
              (PP (IN of)
                (NP
                  (NP (JJ negative) (NN feedback))
                  (CC and)
                  (NP (NN crosstalk) (NN inhibition) (CD -LSB-7) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Recent) (NNS studies))
        (PP (IN with)
          (NP
            (NP (NNS mice))
            (VP (VBG lacking)
              (NP
                (NP (NN SOCS3))
                (CC or)
                (NP (NN SOCS1)))))))
      (VP (VBD revealed)
        (SBAR (IN that)
          (S
            (NP (NN SOCS3))
            (VP (VBZ is)
              (NP
                (NP (DT a) (JJ negative) (NN regulator))
                (PP
                  (PP (IN of)
                    (NP (NN IL-6) (NN signaling)))
                  (CC but)
                  (PP (RB not) (IN of)
                    (NP (NN IL-10) (NN signaling))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Studies))
        (PP (IN of)
          (NP (JJ conditional) (JJ SOCS3-deficient) (NNS mice))))
      (VP (VBP have)
        (VP (VBN shown)
          (SBAR (IN that)
            (S
              (NP
                (NP (NN SOCS3) (NN deficiency))
                (, ,)
                (CONJP (CC but)
                  (RB not))
                (NP (NN SOCS1) (NN deficiency))
                (, ,))
              (VP (VBZ results)
                (PP (IN in)
                  (NP
                    (NP (JJ sustained) (NN activation))
                    (PP (IN of)
                      (NP (NN STAT3)))
                    (PP (IN in)
                      (NP
                        (NP (NN response))
                        (PP (TO to)
                          (NP (NN IL-6) (CD -LSB-8,41))))))))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN analysis))
        (PP (IN of)
          (NP (JJ SOCS3-deficient) (NNS macrophages))))
      (VP (VBZ has)
        (VP (VBN indicated)
          (SBAR (IN that)
            (S
              (NP (NN SOCS3))
              (VP (VBZ is)
                (NP
                  (NP (DT a) (JJ crucial) (NN inhibitor))
                  (PP (IN of)
                    (NP (DT the) (JJ IL-6-induced) (JJ transcriptional) (NN response) (NN -LSB-42)))))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP (NN SOCS3))
      (VP (VBZ is)
        (ADJP (JJ dispensable)
          (PP (IN for)
            (NP (CC both)
              (NP (DT the) (JJ negative) (NN feedback) (NN inhibition))
              (CC and)
              (NP
                (NP (DT the) (JJ immunoregulatory) (NN action))
                (PP (IN of)
                  (NP (NN IL-10)))
                (PP (IN in)
                  (NP (NNS macrophages) (CD -LSB-41))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN On)
        (NP (DT the) (NN contrary)))
      (, ,)
      (NP (NN SOCS1))
      (VP (VBD was)
        (VP (VBN found)
          (S
            (VP (TO to)
              (ADVP (RB directly))
              (VP (VB inhibit)
                (NP (JJ IL-10-mediated) (NN signaling) (NN -LSB-43)))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (VBN Increased) (NN SOCS1) (NN expression))
          (PP (IN in)
            (NP (NN RA) (JJ CD4+) (NN T) (NNS cells))))
        (VP (MD may)
          (ADVP (RB therefore))
          (VP (VB be)
            (VP (VBN associated)
              (PP (IN with)
                (NP
                  (NP (PDT both) (DT the) (JJ impaired) (NN responsiveness))
                  (PP
                    (PP (TO to)
                      (NP (NN IL-10)))
                    (CC and)
                    (PP (TO to)
                      (NP (JJ IL-10-mediated) (NN STAT3) (NN activation))))))))))
      (, ,)
      (CC and)
      (S
        (NP (JJ defective) (NN SOCS3) (NN expression))
        (VP (MD may)
          (VP (VB be)
            (ADJP (JJ responsible)
              (PP (IN for)
                (NP
                  (NP (JJ persistent) (NN STAT3) (NN activation))
                  (PP (IN in)
                    (NP
                      (NP (NN response))
                      (PP (TO to)
                        (NP (NN serum) (NN IL-6))))))))))))
    (. .)))

(
  (S
    (S
      (NP (EX There))
      (VP (VBZ is)
        (NP (DT a) (NN possibility)
          (SBAR (IN that)
            (S
              (NP (NN SOCS1) (NN induction))
              (VP (MD may)
                (VP (VB be)
                  (VP (VBN associated)
                    (PP (IN with)
                      (NP
                        (NP (DT the) (NN ability))
                        (PP (IN of)
                          (NP (JJ CD4+) (NN T) (NNS cells)))
                        (S
                          (VP (TO to)
                            (VP (VB produce)
                              (NP (NN IFN-γ)))))))))))))
        (, ,)
        (SBAR
          (SBAR (IN because)
            (S
              (NP
                (NP (JJ CD4+) (NN T) (NNS cells))
                (PP (IN from)
                  (NP (JJ active) (NN RA))))
              (VP (MD could)
                (VP (VB produce)
                  (NP
                    (NP (JJ high) (NNS levels))
                    (PP (IN of)
                      (NP (NN IFN-γ))))
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN presence))
                      (PP (IN of)
                        (NP (NN IL-10)))))))))
          (, ,)
          (CC and)
          (SBAR (IN because)
            (S
              (NP (NN IFN-γ))
              (VP (VBZ has)
                (VP (VBN been)
                  (VP (VBN known)
                    (PP (IN as)
                      (NP
                        (NP (DT a) (JJ potent) (NN inducer))
                        (PP (IN of)
                          (NP (NN SOCS1) (CD -LSB-32))))))))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBZ is)
        (PP (IN of)
          (NP
            (NP (NN interest))
            (PP (IN in)
              (NP (DT this) (NN regard)))))
        (S
          (VP (TO to)
            (VP (VB indicate)
              (SBAR (IN that)
                (S
                  (NP (VBN polarized)
                    (NP
                      (NP (NN Th1))
                      (CC and)
                      (NP (NN Th2)))
                    (NNS cells))
                  (VP (VBP express)
                    (NP
                      (NP
                        (NP (JJ high) (NNS levels))
                        (PP (IN of)
                          (NP
                            (NP (NN SOCS1))
                            (CC and)
                            (NP (NN SOCS3))
                            (NP (NN mRNA)))))
                      (, ,)
                      (ADVP (RB respectively))
                      (NP (CD -LSB-44) (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (JJ IL-12-induced) (NN STAT4) (NN activation))
        (VP (VBZ is)
          (VP (VBN inhibited)
            (PP (IN by)
              (NP
                (NP (NN SOCS3) (NN induction))
                (PP (IN in)
                  (NP (NN Th2) (NNS cells))))))))
      (, ,) (IN whereas)
      (S
        (NP (JJ IL-4-induced) (NN STAT6) (NN signaling))
        (VP (VBZ is)
          (VP (VBN diminished)
            (PP (IN by)
              (NP
                (NP (NN SOCS1) (NN induction))
                (PP (IN in)
                  (NP (NN Th1) (NNS cells)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN SOCS1))
        (CC and)
        (NP (NN SOCS3)))
      (VP (MD may)
        (ADVP (RB thus))
        (VP (VB have)
          (NP (JJ important) (NNS roles))
          (PP (IN as)
            (NP
              (NP
                (ADJP
                  (ADJP (JJ Th1-specific))
                  (CC and)
                  (ADJP (JJ Th2-specific)))
                (, ,)
                (ADJP (RB mutually) (JJ exclusive))
                (, ,)
                (NP (NN cross-talk))
                (NNS repressors))
              (PP (IN of)
                (NP (DT the)
                  (NP (NN IL-4–STAT6))
                  (CC and)
                  (NP (DT the) (NN IL-12–STAT4) (NN signaling) (NNS pathways))
                  (, ,)
                  (ADVP (RB respectively)))))))))
    (. .)))

(
  (S
    (S
      (S
        (S
          (ADJP (JJ Consistent)
            (PP (IN with)
              (NP (DT this) (NN notion)))))
        (, ,)
        (NP
          (NP (NN PB) (NN T) (NNS cells))
          (PP (IN from)
            (NP
              (NP (NNS patients))
              (PP (IN with)
                (NP (JJ allergic) (NNS diseases))))))
        (ADVP (RB significantly))
        (VP (VBP express)
          (NP
            (NP (JJ high) (NNS levels))
            (PP (IN of)
              (NP (NN SOCS3) (NNS transcripts))))))
      (, ,)
      (CC and)
      (S
        (NP (DT the) (NN SOCS3) (NN expression))
        (VP (VBZ correlates)
          (ADVP (RB well))
          (PP (IN with)
            (NP
              (NP (NN serum) (NN IgE) (NNS levels))
              (CC and)
              (NP (NN disease) (NN pathology) (CD -LSB-45)))))
        (-RRB- -RSB-)))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJR Higher) (NN SOCS1) (NN expression))
        (PP (IN with)
          (NP
            (NP (JJR lower) (NN SOCS3) (NN expression))
            (PP (IN in)
              (NP
                (NP (NN PB) (JJ CD4+) (NN T) (NNS cells))
                (PP (IN from)
                  (NP (NN RA) (NNS patients)))
                (, ,)
                (PP (VBN compared)
                  (PP (IN with)
                    (NP (JJ healthy) (NNS controls))))
                (, ,))))))
      (VP (VBZ is)
        (ADVP (RB therefore))
        (ADJP (RB probably) (JJ consistent)
          (PP (IN with)
            (NP
              (NP (PRP$ their) (JJ systemic) (NN bias))
              (PP (IN towards)
                (NP (DT a) (NN Th1) (NN phenotype))))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBZ has)
              (ADVP (RB previously))
              (VP (VBN been)
                (VP (VBN demonstrated)
                  (NP (CD -LSB-46-49) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (NP (NN Conclusion))))

(
  (S
    (S
      (NP
        (NP (JJ CD4+) (NN T) (NNS cells))
        (PP (IN from)
          (NP (JJ active) (NN RA) (NNS patients))))
      (VP (VBP are)
        (VP (VBN characterized)
          (PP (IN by)
            (NP
              (NP (PRP$ their) (NN resistance))
              (PP (TO to)
                (NP
                  (NP
                    (NP (NN IL-10))
                    (NN inhibition))
                  (PP (IN of)
                    (NP
                      (NP (NN IFN-γ) (NN production))
                      (, ,)
                      (ADJP (JJ due)
                        (PP (TO to)
                          (NP
                            (NP (JJ constitutive) (NN STAT3) (NN phosphorylation))
                            (CC and)
                            (NP (JJ impaired) (JJ IL-10-mediated) (NN STAT3) (NN activation))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ defective) (NN STAT3) (NN signaling))
      (VP (VBZ is)
        (ADVP (RB possibly))
        (VP (VBN associated)
          (PP (IN with)
            (NP
              (NP (NN SOCS1) (NN predominance))
              (PP (IN over)
                (NP (NN SOCS3))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT These) (NNS abnormalities))
        (PP (IN in)
          (NP (JJ active) (NN RA))))
      (VP (VBP are)
        (VP (VBN thought)
          (S
            (VP (TO to)
              (VP (VB be)
                (VP (VBN induced)
                  (ADVP (RB mainly))
                  (PP (IN after)
                    (NP
                      (NP (JJ chronic) (NN exposure))
                      (PP (TO to)
                        (NP
                          (NP (JJ high) (NNS concentrations))
                          (PP (IN of)
                            (NP (NN IL-6))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ limited) (NN efficacy))
        (PP (IN of)
          (NP
            (NP (NN IL-10) (NN treatment))
            (PP (IN of)
              (NP (NN RA) (NNS patients) (CD -LSB-50) (-RRB- -RSB-))))))
      (VP (MD may)
        (VP (VB be)
          (VP (VBN explained)
            (PP (IN in)
              (NP (NN part)))
            (PP (IN by)
              (NP
                (NP (DT the) (NN unresponsiveness))
                (PP (TO to)
                  (NP
                    (NP (NN IL-10))
                    (PP (IN of)
                      (NP
                        (NP (JJ inflammatory) (NNS cells))
                        (, ,)
                        (PP (VBG including)
                          (NP (NN T) (NNS cells)))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (PP (IN On)
          (NP (DT the) (NN contrary)))
        (, ,)
        (NP
          (NP (DT the) (JJ therapeutic) (NN efficacy))
          (PP (IN of)
            (NP (JJ anti-IL-6) (NN receptor) (NN antibody))))
        (VP (VBZ has)
          (VP (VBN been)
            (VP (VBN reported)
              (PP (IN in)
                (NP (NN RA) (NNS patients) (CD -LSB-51) (-RRB- -RSB-)))))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (CD one))
          (PP (IN of)
            (NP
              (NP (DT the) (NNS effects))
              (PP (IN of)
                (NP (DT this) (NN therapy))))))
        (VP (MD may)
          (VP (VB be)
            (S
              (VP (TO to)
                (VP (VB normalize)
                  (NP (NN T) (NNS cells))
                  (PP (IN through)
                    (NP
                      (NP (DT the) (NN inhibition))
                      (PP (IN of)
                        (NP (JJ IL-6-dependent) (NN STAT3) (NN activation))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (ADJP (RBR More) (JJ specific))
          (NN therapy))
        (VP (VBG targeting)
          (NP (NN STAT3) (NN activation))))
      (VP (MD will)
        (VP (VB be)
          (VP (VBN awaited)))))
    (: ;)
    (S
      (PP (IN for)
        (NP
          (NP (NN example))
          (, ,)
          (NP
            (NP (DT the) (NN induction))
            (PP (IN of)
              (NP (DT the) (NN SOCS3) (NN gene))))))
      (, ,)
      (NP
        (NP (DT the) (NN efficacy))
        (PP (IN of)
          (NP (WDT which))))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN demonstrated)
            (PP (IN in)
              (NP (NN animal) (NNS models) (CD -LSB-37) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (NP (NNS Abbreviations))))

(
  (S
    (S
      (VP
        (NP
          (NP
            (NP
              (NP (NN BSA) (JJ =) (JJ bovine) (NN serum) (NN albumin))
              (: ;)
              (NP
                (NP (NN CRP) (JJ =) (JJ C-reactive) (NN protein))
                (: ;)
                (NP (NN ELISA) (JJ =) (JJ enzyme-linked) (JJ immunosorbent) (NN assay))
                (: ;)
                (NP (NN Fc) (JJ =) (NN crystallazibe) (NN fragment))
                (: ;)
                (NP (NN FCS) (JJ =) (JJ fetal) (NN calf) (NN serum))
                (: ;)
                (NP (NN FITC) (JJ =) (NN fluorescein) (NN isothiocyanate)))
              (: ;) (CD IFN-γ))
            (JJ =) (NN interferon) (NN gamma) (: ;) (NN IL) (JJ =) (NN interleukin))
          (: ;)
          (NP (NN IL-10R) (JJ =) (NN interleukin-10) (NN receptor))
          (: ;)
          (NP (NN IL-10R1) (JJ =) (NN type) (CD 1) (NN interleukin-10) (NN receptor) (: ;) (NN JAK) (JJ =) (NN Janus) (NN kinase))
          (: ;)
          (NP (NN mAb) (JJ =) (JJ monoclonal) (NN antibody))
          (: ;)
          (NP (NN MHC) (JJ =) (JJ major) (NN histocompatibility) (NN complex))
          (: ;)
          (NP (NN PB) (JJ =) (JJ peripheral) (NN blood))
          (: ;)
          (NP (NN PBMC) (JJ =) (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
          (: ;))
        (NNS PBS)
        (NP
          (ADJP (JJ =)
            (NP
              (NP (JJ phosphate-buffered) (NN saline))
              (: ;)
              (NP (NN PCR) (JJ =) (NN polymerase) (NN chain) (NN reaction))
              (: ;)
              (NP (NN RA) (JJ =) (JJ rheumatoid) (NN arthritis))
              (: ;)
              (NP
                (NP (NN SOXS) (JJ =) (NN suppressor))
                (PP (IN of)
                  (NP (NN cytokine) (NN signaling))))
              (: ;)
              (NP
                (NP
                  (NP (JJ ST) (JJ =) (JJ synovial) (NN tissue) (: ;) (NN STAT) (JJ =) (NN signal) (NN transducer))
                  (CC and)
                  (NP (NN activator)))
                (PP (IN of)
                  (NP (NN transcription))))
              (: ;)
              (NP (NN Th) (JJ =) (NN T) (NN helper) (NNS cells))
              (: ;) (CD TNF-α)))
          (JJ =) (NN tumor) (NN necrosis) (NN factor) (NN alpha))))
    (. .)))

(
  (S
    (NP (VBG Competing) (NNS interests))))

(
  (S
    (S
      (NP (DT The) (NN author) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))
      (VP (VB declare)
        (SBAR (IN that)
          (S
            (NP (PRP they))
            (VP (VBP have)
              (NP (DT no) (VBG competing) (NNS interests)))))))
    (. .)))

(
  (S
    (NP
      (NP (NNS Authors) (POS '))
      (NNS contributions))))

(
  (S
    (S
      (NP (NN Jiro) (NN Yamana))
      (VP
        (VP (VBD was)
          (ADJP (JJ responsible)
            (PP (IN for)
              (NP
                (NP (DT the) (NNS experiments))
                (CC and)
                (NP (NN data) (NN analysis))))))
        (CC and)
        (VP (VBP wrote)
          (NP (DT the) (NN report)))))
    (. .)))

(
  (S
    (S
      (NP (NN Masahiro) (NN Yamamura))
      (VP
        (VP (VBD was)
          (ADJP (JJ responsible)
            (PP (IN for)
              (NP
                (NP (DT the) (NN planning))
                (PP (IN of)
                  (NP (DT the) (NN research)))))))
        (CC and)
        (VP (VBP wrote)
          (PP (IN up)
            (NP (DT the) (NN manuscript))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNP Akira) (NNP Okamoto) (, ,) (NNP Tetsushi) (NNP Aita))
        (, ,)
        (NP (NNP Mitsuhiro) (NNP Iwahashi))
        (, ,)
        (CC and)
        (NP (NNP Katsue) (NNP Sunahori)))
      (VP (JJ assisted)
        (NP (DT the) (NNS experiments))))
    (. .)))

(
  (S
    (S
      (NP (NN Hirofumi) (NN Makino))
      (ADVP (RB critically))
      (VP (VBN read)
        (NP (DT the) (NN manuscript))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure))
      (CC and)
      (NP (NN Table))
      (NP (NNS captions)))))

(
  (S
    (NP
      (NP (NN Figure) (CD 1))
      (: :)
      (NP
        (NP (NN Dose) (NN response))
        (PP (IN of)
          (NP
            (NP (NN IL-10) (NN inhibition))
            (PP (IN of)
              (NP
                (NP
                  (NP
                    (NP (NN interferon) (NN gamma))
                    (PRN (-LRB- -LRB-)
                      (NP (NN IFN-γ))
                      (-RRB- -RRB-)))
                  (NN production))
                (PP (IN by)
                  (NP (JJ CD4+) (NN T) (NNS cells)))
                (PP (IN after)
                  (NP
                    (NP
                      (NP (NN CD3))
                      (CC and)
                      (NP (NN CD28)))
                    (NN costimulation)))
                (PP
                  (PP (IN in)
                    (NP
                      (NP (NNS patients))
                      (PP (IN with)
                        (NP
                          (NP (JJ rheumatoid) (NN arthritis))
                          (PRN (-LRB- -LRB-)
                            (NP (NN RA))
                            (-RRB- -RRB-))))))
                  (CC and)
                  (PP (IN in)
                    (NP
                      (NP (JJ healthy) (NNS controls))
                      (PRN (-LRB- -LRB-)
                        (NP (NN HC))
                        (-RRB- -RRB-))))))))))
      (. .))))

(
  (S
    (S
      (NP (JJ CD4+) (NN T) (NNS cells))
      (VP (VBD were)
        (VP (VBN purified)
          (PP (IN from)
            (NP
              (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
              (PP (IN of)
                (NP
                  (NP (CD three) (NN RA) (NNS patients))
                  (CC and)
                  (NP (CD three) (NNS HC))))))
          (PP (IN by)
            (NP
              (NP (JJ positive) (NN selection))
              (PP (IN with)
                (NP (JJ anti-CD4) (NN antibody))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ CD4+) (NN T) (NNS cells))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (CD 5) (NN ×) (CD 105) (NNS cells))
            (PP (IN in)
              (NP
                (ADJP (CD 0.5) (NN ml))
                (NN culture) (NN medium)))
            (PP (IN with)
              (NP
                (ADJP (CD 10) (NN %))
                (NN FCS))))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN stimulated)
          (PP (IN by)
            (NP
              (NP (VBN immobilized) (JJ anti-CD3) (NN antibody))
              (CC and)
              (NP (JJ anti-CD28) (NN antibody))))
          (PP (IN in)
            (NP
              (NP (DT the)
                (NP (NN presence))
                (CC or)
                (NP (NN absence)))
              (PP (IN of)
                (NP
                  (NP (JJ diluted) (NN IL-10) (NNS concentrations))
                  (PP (IN for)
                    (NP (CD 36) (NNS hours))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Culture) (NNS supernatants))
      (VP (VBD were)
        (VP (VBN measured)
          (PP (IN for)
            (NP
              (NP (NNS concentrations))
              (PP (IN of)
                (NP (NN IFN-γ)))))
          (PP (IN by)
            (NP (NN ELISA))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN IFN-γ) (NN production))
        (PP (IN with)
          (NP (NN IL-10))))
      (VP (VBD expressed)
        (PP (IN as)
          (NP
            (NP (NN %) (NN IFN-γ))
            (NN production)))
        (PP (IN without)
          (NP (NN IL-10)))))
    (. .)))

(
  (S
    (S
      (NP (NNS Values))
      (VP (VBP are)
        (NP
          (NP (DT the) (NN mean) (NN ±) (JJ standard) (NN error))
          (PP (IN of)
            (NP (DT the) (NN mean))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP
            (NP (NN Figure) (CD 2) (: :)
              (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
              (NN Interferon) (NN gamma))
            (PRN (-LRB- -LRB-)
              (NP (NN IFN-γ))
              (-RRB- -RRB-)))
          (NN production))
        (PP (IN by)
          (NP
            (NP (NN CD3))
            (CC and)
            (NP (NN CD28)))))
      (VP (VBD costimulated)
        (NP (JJ CD4+) (NN T) (NNS cells))
        (PP (IN in)
          (NP
            (NP (DT the) (NN presence))
            (PP (IN of)
              (NP (NN IL-10)))))
        (PP
          (PP (IN in)
            (NP
              (NP (NNS patients))
              (PP (IN with)
                (NP
                  (NP (JJ rheumatoid) (NN arthritis))
                  (PRN (-LRB- -LRB-)
                    (NP (NN RA))
                    (-RRB- -RRB-))))))
          (CC and)
          (PP (IN in)
            (NP
              (NP (JJ healthy) (NNS controls))
              (PRN (-LRB- -LRB-)
                (NP (NN HC))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ CD4+) (NN T) (NNS cells))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (CD 5) (NN ×) (CD 105) (NNS cells))
            (PP (IN in)
              (NP
                (ADJP (CD 0.5) (NN ml))
                (NN culture) (NN medium)))
            (PP (IN with)
              (NP
                (ADJP (CD 10) (NN %))
                (NN FCS))))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN stimulated)
          (PP (IN by)
            (NP
              (NP (JJ anti-CD3) (NN antibody))
              (CC and)
              (NP (JJ anti-CD28) (NN antibody))))
          (PP
            (PP (IN with))
            (CC or)
            (PP (IN without)
              (NP
                (ADJP (CD 1) (NN ng/ml))
                (NN IL-10)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Concentrations))
        (PP (IN of)
          (NP (NN IFN-γ)))
        (PP (IN in)
          (NP (NN culture) (NNS supernatants))))
      (VP (VBD were)
        (VP (VBN measured)
          (PP (IN in)
            (NP (NN duplicate)))
          (PP (IN by)
            (NP (NN ELISA))))))
    (. .)))

(
  (S
    (S
      (NP (NN RA) (NNS patients))
      (VP (VBD were)
        (VP (VBN divided)
          (PP (IN into)
            (NP
              (NP (DT those))
              (PP (IN with)
                (NP
                  (NP
                    (NP (JJ active) (NN disease))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP
                          (NP (JJ multiple) (JJ inflammatory) (NNS joints))
                          (CC and)
                          (NP (NN CRP) (NN level)))
                        (NN ≥) (CD 10) (NN mg/l))
                      (-RRB- -RRB-)))
                  (CC and)
                  (NP
                    (NP (JJ inactive) (NN disease))
                    (PRN (-LRB- -LRB-)
                      (PP (IN in)
                        (NP
                          (NP (NN remission))
                          (CC and)
                          (NP (NN CRP) (NN level))))
                      (NP (NN ≤) (CD 4) (NN mg/l))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS results))
      (VP (VBP are)
        (VP (VBN represented)
          (PP (IN as)
            (NP (DT a) (NN box) (NN plot))))
        (PRN (: ;)
          (NP
            (ADJP
              (ADJP (JJ upper))
              (CC and)
              (ADJP (JJR lower)))
            (NNS bars))
          (, ,)
          (NP
            (NP
              (ADJP
                (ADJP (JJ 90th))
                (CC and)
                (ADJP (JJ 10th)))
              (NNS percentiles))
            (, ,)
            (ADVP (RB respectively)))
          (: ;)
          (NP (JJ upper))
          (, ,)
          (NP
            (NP
              (NP
                (NP (NN center))
                (CC and)
                (NP (JJR lower) (NNS lines)))
              (PP (IN of)
                (NP
                  (NP (NN box))
                  (, ,)
                  (NP (NN 75th))
                  (, ,)
                  (NP (NN 50th))
                  (, ,)
                  (CC and)
                  (NP (NN 25th) (NNS percentiles)))))
            (, ,)
            (ADVP (RB respectively))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))
          (NN Percentage))
        (PP (IN of)
          (NP (NN IFN-γ) (NN production)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN IFN-γ) (NN production))
        (PP (IN with)
          (NP (NN IL-10))))
      (VP (VBD expressed)
        (PP (IN as)
          (NP
            (NP (NN %) (NN IFN-γ))
            (NN production)))
        (PP (IN without)
          (NP (NN IL-10)))))
    (. .)))

(
  (S
    (S
      (NP (NNS Values))
      (VP (VBP are)
        (NP
          (NP (DT the) (NN mean) (NN ±) (JJ standard) (NN error))
          (PP (IN of)
            (NP (DT the) (NN mean))))))
    (. .)))

(
  (S
    (S
      (NP (NN n))
      (, ,)
      (NP
        (NP (NN number))
        (PP (IN of)
          (NP
            (NP (NNS samples))
            (VP (VBN tested))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 3))
      (: :)
      (NP
        (NP
          (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
          (NN Cell) (NN surface) (NN expression))
        (PP (IN of)
          (NP
            (NP (NN type) (CD 1) (NN interleukin-10) (NN receptor))
            (PRN (-LRB- -LRB-)
              (NP (NN IL-10R1))
              (-RRB- -RRB-))))
        (PP (IN on)
          (NP
            (NP (JJ CD4+) (NN T) (NNS cells))
            (PP
              (PP (IN from)
                (NP
                  (NP (NNS patients))
                  (PP (IN with)
                    (NP
                      (NP (JJ rheumatoid) (NN arthritis))
                      (PRN (-LRB- -LRB-)
                        (NP (NN RA))
                        (-RRB- -RRB-))))))
              (CC and)
              (PP (IN from)
                (NP
                  (NP (JJ healthy) (NNS controls))
                  (PRN (-LRB- -LRB-)
                    (NP (NN HC))
                    (-RRB- -RRB-))))))))
      (. .))))

(
  (S
    (S
      (NP (JJ Peripheral) (NN blood) (JJ mononuclear) (NNS cells))
      (VP
        (VP (VBD were)
          (VP (VBN stained)
            (PP
              (PP (IN with)
                (NP (JJ anti-IL-10R1) (NN antibody)))
              (CC or)
              (PP (IN with)
                (NP (JJ isotype-matched) (JJ control) (NN antibody))))
            (, ,)
            (S
              (VP (VBN followed)
                (PP (IN by)
                  (NP
                    (NP (NN incubation))
                    (PP (IN with)
                      (NP (JJ FITC-conjugated) (NN goat) (JJ anti-mouse) (NN IgG1) (JJ polyclonal) (NN antibody)))))))))
        (, ,)
        (CC and)
        (VP (VBD were)
          (ADVP (RB then))
          (VP (VBN stained)
            (PP (IN with)
              (NP (JJ phycoerythrin-conjugated) (JJ anti-CD4) (NN mAb)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN expression))
        (PP (IN of)
          (NP
            (NP (NN CD4))
            (CC and)
            (NP (NN IL-10R1)))))
      (VP (VBD was)
        (VP (VBN determined)
          (PP (IN by)
            (NP (NN flow) (JJ cytometric) (NN analysis))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Representative) (JJ histographic) (NNS patterns))
        (PP (IN of)
          (NP
            (NP (NN IL-10R1) (NN expression))
            (PP (IN on)
              (NP
                (NP (JJ CD4+) (NN T) (NNS cells))
                (PP (IN from)
                  (NP
                    (NP (NN RA) (NNS patients))
                    (CC and)
                    (NP (NNS HC)))))))))
      (VP (VBP are)
        (VP (VBN shown))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))
      (NP
        (NP (DT The) (NN intensity))
        (PP (IN of)
          (NP (NN IL-10R1)))
        (PP (IN on)
          (NP (JJ CD4+) (NN T) (NNS cells))))
      (VP (VBD was)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (DT the) (NN ratio))
              (PP (IN of)
                (NP
                  (NP
                    (NP (DT the) (JJ mean) (NN fluorescence) (NN intensity))
                    (-LRB- -LRB-)
                    (NP (NN MFI))
                    (-RRB- -RRB-))
                  (PP (IN of)
                    (S
                      (VP (VBG staining)
                        (PP (IN with)
                          (NP
                            (NP (NN anti-IL-10R1))
                            (PP (TO to)
                              (NP (JJ control) (NN antibody)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Values))
      (VP (VBP are)
        (NP
          (NP (DT the) (NN mean) (NN ±) (JJ standard) (NN error))
          (PP (IN of)
            (NP (DT the) (NN mean))))))
    (. .)))

(
  (S
    (S
      (NP (NN n))
      (, ,)
      (NP
        (NP (NN number))
        (PP (IN of)
          (NP
            (NP (NNS samples))
            (VP (VBN tested))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 4))
      (: :)
      (NP
        (NP
          (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
          (JJ IL-10-mediated) (NN phosphorylation))
        (PP (IN of)
          (NP
            (NP
              (NP (NN signal) (NN transducer))
              (CC and)
              (NP (NN activator)))
            (PP (IN of)
              (NP
                (NP (NN transcription) (-LRB- -LRB-) (NN STAT) (-RRB- -RRB-) (CD 1))
                (CC and)
                (NP (NN STAT3))))))
        (PP (IN in)
          (NP
            (NP (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP
                (NP (NNS patients))
                (PP
                  (PP (IN with)
                    (NP
                      (NP (JJ rheumatoid) (NN arthritis))
                      (PRN (-LRB- -LRB-)
                        (NP (NN RA))
                        (-RRB- -RRB-))))
                  (CC and)
                  (PP (IN from)
                    (NP
                      (NP (JJ healthy) (NNS controls))
                      (PRN (-LRB- -LRB-)
                        (NP (NN HC))
                        (-RRB- -RRB-))))))))))
      (. .))))

(
  (S
    (S
      (S
        (NP
          (NP (JJ CD4+) (NN T) (NNS cells))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (CD 5) (NN ×) (CD 105) (NNS cells))
              (PP (IN in)
                (NP
                  (ADJP (CD 0.5) (NN ml))
                  (NN culture) (NN medium)))
              (PP (IN with)
                (NP
                  (ADJP (CD 10) (NN %))
                  (NN FCS))))
            (-RRB- -RRB-)))
        (VP (VBD were)
          (VP (VBN incubated)
            (PP
              (PP (IN with))
              (CC or)
              (PP (IN without)
                (NP
                  (NP (NN IL-10))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (QP (CD 1)
                        (CC and)
                        (CD 10))
                      (NN ng/ml))
                    (-RRB- -RRB-))))))))
      (CC and)
      (S
        (NP (NNS cells))
        (VP (VBD were)
          (VP (VBN harvested)
            (ADVP
              (NP (CD 20) (NN min))
              (RB later))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (JJ Whole) (NN cell) (NNS extracts))
        (VP (VBD were)
          (VP (VBN prepared)
            (PP (IN by)
              (S
                (VP (VBG placing)
                  (NP (NNS cells))
                  (PP (IN in)
                    (NP (NN SDS) (NN buffer)))))))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP
            (NP (NN tyrosine) (NN phosophorylation))
            (PRN (-LRB- -LRB-)
              (NP (NN p-Tyr))
              (-RRB- -RRB-)))
          (PP (IN of)
            (NP
              (NP (NN STAT1))
              (CC and)
              (NP (NN STAT3)))))
        (VP (VBD was)
          (VP (VBN detected)
            (PP (IN by)
              (NP (NN western) (NN blot) (NN analysis)))))))
    (. .)))

(
  (S
    (S
      (NP (JJ IFN-γ-stimulated) (NN Hela) (NNS cells))
      (VP (VBD were)
        (VP (VBN used)
          (PP (IN as)
            (NP
              (NP (DT a) (JJ positive) (NN control))
              (PP (IN for)
                (NP (NN STAT1) (NN phosphorylation))))))))
    (. .)))

(
  (S
    (NP
      (NP (-LRB- -LRB-) (NN b) (-RRB- -RRB-) (NN Percentage))
      (PP (IN of)
        (NP (JJ IL-10-activated) (NN STAT3) (NN phosphorylation)))
      (PP (IN in)
        (NP
          (NP (JJ CD4+) (NN T) (NNS cells))
          (PP
            (PP (IN from)
              (NP (NN RA) (NNS patients)))
            (CC and)
            (PP (IN from)
              (NP (NN HC))))))
      (. .))))

(
  (S
    (S
      (S
        (NP (NN Protein) (NNS bands))
        (VP (VBD were)
          (VP (VBN quantified)
            (PP (IN by)
              (NP (NN densitometry)))
            (S
              (VP (VBG using)
                (NP (NN NIH-Image) (NN analysis)))))))
      (, ,)
      (CC and)
      (S
        (NP (NN STAT3) (NN phosphorylation))
        (VP (VBD was)
          (VP (VBN expressed)
            (PP (IN as)
              (NP (NN %) (JJ total) (NN STAT3) (NN protein)))))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-))
      (NP (NN STAT3))
      (VP (NN phosphorylation)
        (PP (IN in)
          (NP
            (NP (JJ ST) (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP (NN RA) (NNS patients)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Representative) (NNS results))
        (PP (IN of)
          (NP (NN STAT3) (NN phosphorylation)))
        (PP (IN in)
          (NP
            (NP (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP
                (NP
                  (NP
                    (NP (CD three) (JJ synovial) (NN tissue) (NNS samples))
                    (PP (IN of)
                      (NP (NN RA) (NNS patients))))
                  (CC and)
                  (NP (CD three) (JJ peripheral) (NN blood) (NNS samples)))
                (PP (IN of)
                  (NP (NN HC))))))))
      (VP (VBP are)
        (VP (VBN shown))))
    (. .)))

(
  (S
    (S
      (NP (NNS Values))
      (VP (VBP are)
        (NP
          (NP (DT the) (NN mean) (NN ±) (JJ standard) (NN error))
          (PP (IN of)
            (NP (DT the) (NN mean))))))
    (. .)))

(
  (S
    (S
      (NP (NN n))
      (, ,)
      (NP
        (NP (NN number))
        (PP (IN of)
          (NP
            (NP (NNS samples))
            (VP (VBN tested))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 5))
      (: :)
      (NP
        (NP
          (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
          (NN Activation))
        (PP (IN of)
          (NP
            (NP (NN signal)
              (NP
                (NP
                  (NP (NN transducer))
                  (CC and)
                  (NP (NN activator)))
                (PP (IN of)
                  (NP (NN transcription) (-LRB- -LRB-) (NN STAT) (-RRB- -RRB-) (CD 3)))))
            (PP (IN in)
              (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells)))))
        (PP (IN by)
          (NP
            (NP (NN serum) (NN IL-6))
            (PP (IN from)
              (NP
                (NP (NNS patients))
                (PP (IN with)
                  (NP
                    (NP (JJ rheumatoid) (NN arthritis))
                    (PRN (-LRB- -LRB-)
                      (NP (NN RA))
                      (-RRB- -RRB-)))))))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (JJ CD4+) (NN T) (NNS cells))
        (PP (IN from)
          (NP
            (NP (JJ healthy) (NNS controls))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (CD 5) (NN ×) (CD 105) (NNS cells))
                (PP (IN in)
                  (NP
                    (ADJP (CD 0.5) (NN ml))
                    (NN culture) (NN medium))))
              (-RRB- -RRB-)))))
      (VP (VBD were)
        (VP (VBN stimulated)
          (PP (IN by)
            (NP
              (ADJP (CD 30) (NN %))
              (NN RA) (NN serum)))
          (PP (IN in)
            (NP
              (NP (DT the) (NN presence))
              (PP
                (PP (IN of)
                  (NP (VBG neutralizing)
                    (NP
                      (NP
                        (NP (JJ anti-IL-6) (NN antibody))
                        (PRN (-LRB- -LRB-)
                          (NP (NN Ab))
                          (-RRB- -RRB-)))
                      (PRN (-LRB- -LRB-)
                        (NP (CD 40) (NN μg/ml))
                        (-RRB- -RRB-)))))
                (CC or)
                (PP (IN of)
                  (NP
                    (NP
                      (NP (JJ control) (NN antibody))
                      (PRN (-LRB- -LRB-)
                        (NP (CD 40) (NN μg/ml))
                        (-RRB- -RRB-)))
                    (PP (IN for)
                      (NP (CD 20) (NN min)))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Phosophorylation))
      (PP (IN of)
        (NP
          (NP (NN STAT1))
          (CC and)
          (NP (NN STAT3)))))
    (VP (VBD was)
      (VP (VBN detected)
        (PP (IN by)
          (NP (NN western) (NN blot) (NN analysis.)))))
    (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))))

(
  (S
    (NP
      (NP (NN Effect))
      (PP (IN of)
        (NP (NN IL-6) (NN pretreatment)))
      (PP (IN on)
        (NP
          (NP (NN IL-10) (NN inhibition))
          (PP (IN of)
            (NP (NN IFN-γ) (NN production)))
          (PP (IN by)
            (NP (JJ CD4+) (NN T) (NNS cells)))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (JJ CD4+) (NN T) (NNS cells))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (CD 5) (NN ×) (CD 105) (NNS cells))
            (PP (IN in)
              (NP
                (ADJP (CD 0.5) (NN ml))
                (NN culture) (NN medium)))
            (PP (IN with)
              (NP
                (ADJP (CD 10) (NN %))
                (NN FCS))))
          (-RRB- -RRB-)))
      (VP
        (VP (VBD were)
          (VP (VBN incubated)
            (PP
              (PP (IN with))
              (CC or)
              (PP (IN without)
                (NP
                  (NP (NN IL-6))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 10) (NN ng/ml))
                    (-RRB- -RRB-)))))
            (PP (IN for)
              (NP (CD 36) (NNS hours)))))
        (, ,)
        (CC and)
        (VP (VBD were)
          (ADVP (RB then))
          (VP (VBN stimulated)
            (PP (IN by)
              (NP
                (NP (JJ anti-CD3) (NN antibody))
                (CC and)
                (NP (JJ anti-CD28) (NN antibody))))
            (PP (IN in)
              (NP
                (NP (DT the)
                  (NP (NN presence))
                  (CC or)
                  (NP (NN absence)))
                (PP (IN of)
                  (NP
                    (NP
                      (NP (NN IL-10))
                      (PRN (-LRB- -LRB-)
                        (NP (CD 1) (NN ng/ml))
                        (-RRB- -RRB-)))
                    (PP (IN for)
                      (NP (CD 36) (NNS hours)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Concentrations))
        (PP (IN of)
          (NP (NN IFN-γ)))
        (PP (IN in)
          (NP (NN culture) (NNS supernatants))))
      (VP (VBD were)
        (VP (VBN measured)
          (PP (IN in)
            (NP (NN duplicate)))
          (PP (IN by)
            (NP (NN ELISA))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN IFN-γ) (NN production))
        (PP (IN with)
          (NP (NN IL-10))))
      (VP (VBD was)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (NN %) (NN IFN-γ) (NN production))
              (PP (IN without)
                (NP (NN IL-10))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Values))
      (VP (VBP are)
        (NP
          (NP (DT the) (NN mean) (NN ±) (JJ standard) (NN error))
          (PP (IN of)
            (NP (DT the) (NN mean))))))
    (. .)))

(
  (S
    (S
      (NP (NN n))
      (, ,)
      (NP
        (NP (NN number))
        (PP (IN of)
          (NP
            (NP (NNS samples))
            (VP (VBN tested))))))
    (. .)))

(
  (S
    (NP
      (NP (NN P-Tyr))
      (, ,)
      (NP (NN tyrosine) (NN phosophorylation))
      (. .))))

(
  (S
    (NP
      (NP (NN Figure) (CD 6))
      (: :)
      (NP
        (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
        (NP (DT The) (NN mRNA) (NN expression))
        (PP (IN of)
          (NP
            (NP (NN SOCS1))
            (CC and)
            (NP (NN SOCS3))))
        (PP (IN in)
          (NP
            (NP (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP
                (NP
                  (NP (NNS patients))
                  (PP (IN with)
                    (NP (NN RA))))
                (CC and)
                (NP
                  (NP (JJ healthy) (NNS controls))
                  (PRN (-LRB- -LRB-)
                    (NP (NN HC))
                    (-RRB- -RRB-))))))))
      (. .))))

(
  (S
    (S
      (S
        (NP (JJ Total) (JJ cellular) (NN RNA))
        (VP (VBD was)
          (VP (VBN extracted)
            (PP (IN from)
              (NP
                (ADJP (RB freshly) (VBN isolated))
                (JJ CD4+) (NN T) (NNS cells))))))
      (CC and)
      (S
        (NP
          (NP (NN mRNA) (NN expression))
          (PP (IN of)
            (NP
              (NP (NN SOCS1))
              (CC and)
              (NP (NN SOCS3)))))
        (VP (VBD was)
          (VP (VBN analyzed)
            (PP (IN by)
              (NP (JJ real) (NN time-PCR)))
            (SBAR (IN as)
              (S
                (VP (VBN described)
                  (PP (IN in)
                    (NP
                      (NP (NNS Patients))
                      (CC and)
                      (NP (NNS Methods)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Levels))
        (PP (IN of)
          (NP
            (NP (NN SOCS1))
            (CC and)
            (NP (NN SOCS3))
            (NP (NNS mRNAs)))))
      (VP (VBD were)
        (VP (VBN normalized)
          (PP (JJ relative) (TO to)
            (NP (NN β-actin) (NN expression))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Values))
      (VP (VBP are)
        (NP
          (NP (DT the)
            (ADJP (NN mean) (NN ±) (NN SEM.) (NN n) (JJ =))
            (NN number))
          (PP (IN of)
            (NP
              (NP (NNS samples))
              (VP (VBN tested)))))))
    (. .)))

(
  (S
    (NP
      (NP (-LRB- -LRB-) (NN b) (-RRB- -RRB-) (NN Kinetics))
      (PP (IN of)
        (NP (JJ IL-6-induced) (NN SOCS1) (NN mRNA) (NN expression)))
      (PP (IN in)
        (NP (JJ normal) (JJ CD4+) (NN T) (NNS cells)))
      (. .))))

(
  (S
    (S
      (S
        (NP
          (NP
            (NP (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP (NN HC))))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (CD 5) (NN ×) (CD 105) (NNS cells))
              (PP (IN in)
                (NP
                  (NP (CD 0.5) (NN ml))
                  (PP (IN of)
                    (NP (NN culture) (NN medium)))))
              (PP (IN with)
                (NP
                  (ADJP (CD 10) (NN %))
                  (NN FCS))))
            (-RRB- -RRB-)))
        (VP (VBD were)
          (VP (VBN stimulated)
            (PP (IN with)
              (NP
                (NP (NN IL-6))
                (PRN (-LRB- -LRB-)
                  (NP (CD 10) (NN ng/ml))
                  (-RRB- -RRB-)))))))
      (CC and)
      (S
        (NP (NN SOCS1) (NN mRNA) (NN expression))
        (VP (VBD was)
          (VP (VBN determined)
            (PP (IN at)
              (NP
                (NP (DT the) (VBN indicated) (NN time))
                (PP (IN after)
                  (NP (NN stimulation)))))))))
    (. .)))

